postcomposition_id	descriptor_id	assertion_id	disorder_id	disorder_name	source_file	section	section_index	section_name	section_description	descriptor_path	descriptor_preferred_term	descriptor_term_id	descriptor_term_label	relation_type	relation_index	relation_path	predicate_preferred_term	predicate_term_id	predicate_term_label	value_preferred_term	value_term_id	value_term_label	value_literal	raw_json
1	32	27	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	0	ALK Gene Rearrangement	ALK rearrangements result from chromosomal inversions or translocations that fuse the ALK kinase domain to an N-terminal partner gene (usually EML4). The partner provides a dimerization domain, causing constitutive ALK kinase activation independent of ligand.	biological_processes[0]	protein kinase activity	GO:0004672	protein kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
2	33	28	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ALK Signaling	The EML4-ALK fusion protein is constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
3	34	28	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ALK Signaling	The EML4-ALK fusion protein is constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
4	35	28	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ALK Signaling	The EML4-ALK fusion protein is constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration.	biological_processes[2]	JAK-STAT cascade	GO:0007259	JAK-STAT cascade	modifier	0	biological_processes[2].modifier	modifier						INCREASED	"""INCREASED"""
5	36	29	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	2	Oncogene Addiction	ALK-rearranged tumors exhibit oncogene addiction, becoming dependent on continued ALK signaling for survival. ALK inhibition leads to dramatic tumor responses, often within days to weeks of starting therapy.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
6	37	30	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	3	ALK TKI Resistance	Resistance to ALK TKIs develops through ALK-dependent mechanisms (secondary mutations like G1202R, compound mutations) or ALK-independent bypass pathways (MET, EGFR, KRAS). Later-generation TKIs (lorlatinib) overcome most single ALK mutations.	biological_processes[0]	response to drug	GO:0042493	response to drug	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
7	49	45	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	0	PML-RARA Fusion Oncogene Formation	The t(15;17)(q24;q21) translocation fuses the PML gene on chromosome 15 with the retinoic acid receptor alpha (RARA) gene on chromosome 17. The resulting fusion protein retains the DNA-binding and ligand-binding domains of RARA but gains aberrant properties from PML, including enhanced corepressor recruitment and altered subnuclear localization.	biological_processes[0]	myeloid cell differentiation	GO:0030099	myeloid cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
8	51	46	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	1	Transcriptional Repression of Differentiation Genes	PML-RARA binds retinoic acid response elements but recruits corepressor complexes (NCoR, SMRT, HDACs) at physiological retinoic acid concentrations. This silences RARA target genes required for granulocyte differentiation, causing a differentiation block at the promyelocyte stage. Pharmacological doses of ATRA overcome this block.	biological_processes[0]	granulocyte differentiation	GO:0030851	granulocyte differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
9	52	47	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	2	PML Nuclear Body Disruption	Wild-type PML organizes nuclear bodies that regulate multiple cellular processes including apoptosis and senescence. PML-RARA disrupts PML nuclear bodies into a microspeckled pattern, impairing PML tumor suppressor functions. Arsenic trioxide restores PML nuclear bodies and induces PML-RARA degradation.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
10	53	48	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	3	Impaired Tumor Suppression	Disruption of PML nuclear bodies impairs p53-mediated senescence and apoptosis pathways. This contributes to the survival and accumulation of leukemic promyelocytes.	biological_processes[0]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
11	56	50	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	5	Coagulopathy	APL promyelocytes release tissue factor and cancer procoagulant from azurophilic granules, triggering disseminated intravascular coagulation. Annexin II expression promotes plasmin generation causing hyperfibrinolysis. This combination causes severe, often fatal bleeding before and during early treatment.	biological_processes[0]	blood coagulation	GO:0007596	blood coagulation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
12	62	56	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	0	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			all-trans-retinoic acid	CHEBI:15367	all-trans-retinoic acid		"{""preferred_term"": ""all-trans-retinoic acid"", ""term"": {""id"": ""CHEBI:15367"", ""label"": ""all-trans-retinoic acid""}}"
13	64	57	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	1	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			arsenic trioxide	CHEBI:30621	diarsenic trioxide		"{""preferred_term"": ""arsenic trioxide"", ""term"": {""id"": ""CHEBI:30621"", ""label"": ""diarsenic trioxide""}}"
14	123	117	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling	"The FGFR3 G380R mutation causes constitutive activation of the receptor, leading to enhanced downstream signaling through STAT1, MAPK, and other pathways. This results in premature cell cycle arrest of growth plate chondrocytes, reduced chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation. The receptor normally serves as a negative regulator of bone growth; its overactivation leads to the shortened long bones characteristic of achondroplasia.
"	gene	FGFR3	hgnc:3690	FGFR3	modifier	0	gene.modifier	modifier						INCREASED	"""INCREASED"""
15	195	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	treatment_term	retinoid agent therapy	MAXO:0000237	retinoid agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	retinoid	NCIT:C68299	Retinoid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""retinoid"", ""term"": {""id"": ""NCIT:C68299"", ""label"": ""Retinoid""}}}"
16	198	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	treatment_term	retinoid agent therapy	MAXO:0000237	retinoid agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	trifarotene	NCIT:C118577	Trifarotene		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""trifarotene"", ""term"": {""id"": ""NCIT:C118577"", ""label"": ""Trifarotene""}}}"
17	201	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	treatment_term	antimicrobial agent therapy	MAXO:0001021	antimicrobial agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	benzoyl peroxide	NCIT:C47411	Benzoyl Peroxide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}"
18	204	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	treatment_term	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	antibiotic	NCIT:C258	Antibiotic		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""antibiotic"", ""term"": {""id"": ""NCIT:C258"", ""label"": ""Antibiotic""}}}"
19	207	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	clindamycin phosphate	NCIT:C47978	Clindamycin Phosphate		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""clindamycin phosphate"", ""term"": {""id"": ""NCIT:C47978"", ""label"": ""Clindamycin Phosphate""}}}"
20	207	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	adapalene	NCIT:C28989	Adapalene		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adapalene"", ""term"": {""id"": ""NCIT:C28989"", ""label"": ""Adapalene""}}}"
21	207	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	2	treatment_term.qualifiers[2]	therapeutic agent	NCIT:C2259	Therapeutic Agent	benzoyl peroxide	NCIT:C47411	Benzoyl Peroxide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}"
22	214	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	treatment_term	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	tetracycline antibiotic	NCIT:C1595	Tetracycline Antibiotic		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tetracycline antibiotic"", ""term"": {""id"": ""NCIT:C1595"", ""label"": ""Tetracycline Antibiotic""}}}"
23	217	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	treatment_term	retinoid agent therapy	MAXO:0000237	retinoid agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	isotretinoin	NCIT:C603	Isotretinoin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""isotretinoin"", ""term"": {""id"": ""NCIT:C603"", ""label"": ""Isotretinoin""}}}"
24	220	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term	hormone modifying therapy	MAXO:0000283	hormone modifying therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	oral contraceptive	NCIT:C389	Oral Contraceptive		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""oral contraceptive"", ""term"": {""id"": ""NCIT:C389"", ""label"": ""Oral Contraceptive""}}}"
25	220	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term	hormone modifying therapy	MAXO:0000283	hormone modifying therapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	spironolactone	NCIT:C840	Spironolactone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}"
26	225	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	chemical peel	NCIT:C93203	Chemical Peel		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}"
27	228	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	chemical peel	NCIT:C93203	Chemical Peel		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}"
28	228	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	azelaic acid	NCIT:C47407	Azelaic Acid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azelaic acid"", ""term"": {""id"": ""NCIT:C47407"", ""label"": ""Azelaic Acid""}}}"
29	233	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	chemical peel	NCIT:C93203	Chemical Peel		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}"
30	233	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	glycolic acid	NCIT:C83737	Glycolic Acid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""glycolic acid"", ""term"": {""id"": ""NCIT:C83737"", ""label"": ""Glycolic Acid""}}}"
31	233	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	2	treatment_term.qualifiers[2]	therapeutic agent	NCIT:C2259	Therapeutic Agent	topical trichloroacetic acid	NCIT:C125002	Topical Trichloroacetic Acid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical trichloroacetic acid"", ""term"": {""id"": ""NCIT:C125002"", ""label"": ""Topical Trichloroacetic Acid""}}}"
32	240	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	laser therapy	NCIT:C15466	Laser Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}"
33	243	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	vitamin C	NCIT:C68507	Vitamin C		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vitamin C"", ""term"": {""id"": ""NCIT:C68507"", ""label"": ""Vitamin C""}}}"
34	243	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	topical vitamin E	NCIT:C67081	Topical Vitamin E		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical vitamin E"", ""term"": {""id"": ""NCIT:C67081"", ""label"": ""Topical Vitamin E""}}}"
35	248	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	phototherapy	NCIT:C15301	Phototherapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}"
36	251	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	phototherapy	NCIT:C15301	Phototherapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}"
37	254	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	photodynamic therapy	NCIT:C15300	Photodynamic Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""photodynamic therapy"", ""term"": {""id"": ""NCIT:C15300"", ""label"": ""Photodynamic Therapy""}}}"
38	257	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	laser therapy	NCIT:C15466	Laser Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}"
39	257	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	platelet-rich plasma	NCIT:C106557	Platelet-rich Plasma		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""platelet-rich plasma"", ""term"": {""id"": ""NCIT:C106557"", ""label"": ""Platelet-rich Plasma""}}}"
40	262	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	laser therapy	NCIT:C15466	Laser Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}"
41	262	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	1	treatment_term.qualifiers[1]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	infrared laser therapy	NCIT:C66918	Infrared Laser Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""infrared laser therapy"", ""term"": {""id"": ""NCIT:C66918"", ""label"": ""Infrared Laser Therapy""}}}"
42	290	223	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	5	AIDS-related Cancers	Weakened immune surveillance increases risk of certain cancers.	biological_processes[0]	immune response to tumor cell	GO:0002418	immune response to tumor cell	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
43	311	255	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	1	Reduced Cortisol Production	Lack of cortisol impacts the body's ability to respond to stress and maintain various metabolic functions. Impaired gluconeogenesis, decreased vascular tone, and altered immune responses result from cortisol deficiency.	biological_processes[0]	glucocorticoid biosynthetic process	GO:0006704	glucocorticoid biosynthetic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
44	312	255	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	1	Reduced Cortisol Production	Lack of cortisol impacts the body's ability to respond to stress and maintain various metabolic functions. Impaired gluconeogenesis, decreased vascular tone, and altered immune responses result from cortisol deficiency.	biological_processes[1]	gluconeogenesis	GO:0006094	gluconeogenesis	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
45	313	255	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	1	Reduced Cortisol Production	Lack of cortisol impacts the body's ability to respond to stress and maintain various metabolic functions. Impaired gluconeogenesis, decreased vascular tone, and altered immune responses result from cortisol deficiency.	biological_processes[2]	response to stress	GO:0006950	response to stress	modifier	0	biological_processes[2].modifier	modifier						ABNORMAL	"""ABNORMAL"""
46	314	256	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	2	Reduced Aldosterone Production	Insufficient aldosterone affects the balance of sodium and potassium in the body, leading to dehydration and low blood pressure. Impaired sodium retention and potassium excretion in renal tubules cause electrolyte disturbances.	biological_processes[0]	mineralocorticoid biosynthetic process	GO:0006705	mineralocorticoid biosynthetic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
47	315	256	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	2	Reduced Aldosterone Production	Insufficient aldosterone affects the balance of sodium and potassium in the body, leading to dehydration and low blood pressure. Impaired sodium retention and potassium excretion in renal tubules cause electrolyte disturbances.	biological_processes[1]	sodium ion transport	GO:0006814	sodium ion transport	modifier	0	biological_processes[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
48	316	256	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	2	Reduced Aldosterone Production	Insufficient aldosterone affects the balance of sodium and potassium in the body, leading to dehydration and low blood pressure. Impaired sodium retention and potassium excretion in renal tubules cause electrolyte disturbances.	biological_processes[2]	potassium ion transport	GO:0006813	potassium ion transport	modifier	0	biological_processes[2].modifier	modifier						ABNORMAL	"""ABNORMAL"""
49	328	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	biological_processes[0]	negative regulation of T cell receptor signaling pathway	GO:0050860	negative regulation of T cell receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
50	329	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	biological_processes[1]	antigen processing and presentation	GO:0019882	antigen processing and presentation	modifier	0	biological_processes[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
51	330	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	biological_processes[2]	inflammatory response	GO:0006954	inflammatory response	modifier	0	biological_processes[2].modifier	modifier						INCREASED	"""INCREASED"""
52	351	291	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	1	Tax-Mediated NF-kappaB Activation	Tax activates both canonical and non-canonical NF-kappaB pathways through direct interaction with IKK complex and NIK. Constitutive NF-kappaB activation drives expression of anti-apoptotic genes (BCL-XL, cIAP, survivin), cytokines (IL-2, IL-15), and cell cycle regulators, promoting T-cell survival and proliferation.	biological_processes[0]	positive regulation of NF-kappaB transcription factor activity	GO:0051092	positive regulation of NF-kappaB transcription factor activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
53	352	292	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	2	Genomic Instability and Accumulation of Mutations	Tax impairs multiple DNA repair pathways including nucleotide excision repair, base excision repair, and double-strand break repair. This leads to accumulation of somatic mutations over the decades-long latency period. Tax also causes aneuploidy through centrosome amplification and mitotic checkpoint dysfunction.	biological_processes[0]	DNA damage response	GO:0006974	DNA damage response	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
54	353	293	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	3	Apoptosis Resistance	Multiple mechanisms contribute to apoptosis resistance: NF-kappaB-mediated upregulation of BCL-XL and cIAP, Tax-mediated p53 inhibition, and HBZ-mediated enhancement of regulatory T-cell survival. This allows accumulation of cells with genomic abnormalities.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
55	355	294	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	4	Uncontrolled T-Cell Proliferation	Combined effects of constitutive NF-kappaB activation, accumulated mutations, and apoptosis resistance result in clonal expansion of HTLV-1-infected T cells. ATLL cells acquire a CD4+CD25+FOXP3+ regulatory T-cell phenotype with immunosuppressive properties.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
56	372	316	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	1	TP53 R249S Hotspot Mutation	The aflatoxin-DNA adduct forms preferentially at the third position of codon 249 in TP53, causing a G>T transversion that results in arginine-to-serine substitution (R249S). This mutation is found in approximately 50% of HCCs in high-aflatoxin regions but is rare in low-exposure areas. The R249S mutation impairs p53 DNA binding and transcriptional activity, eliminating its tumor suppressor function.	biological_processes[0]	DNA damage response	GO:0006974	DNA damage response	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
57	373	317	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	2	HBV-Aflatoxin Synergistic Interaction	HBV and aflatoxin interact synergistically through multiple mechanisms: HBV-induced chronic inflammation increases hepatocyte proliferation, allowing fixation of aflatoxin-induced mutations; HBx protein inhibits DNA repair; and viral integration may disrupt tumor suppressor genes. The multiplicative interaction results in approximately 60-fold increased HCC risk compared to unexposed individuals.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
58	374	318	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	3	Loss of Cell Cycle Checkpoint Control	TP53 R249S mutation combined with HBx-mediated p53 inhibition and Rb pathway inactivation results in loss of cell cycle checkpoint control. Cells with DNA damage continue to proliferate, accumulating additional mutations.	biological_processes[0]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
59	375	319	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	4	Apoptosis Resistance	Loss of functional p53 impairs the intrinsic apoptotic pathway in response to DNA damage. Combined with HBV-associated survival signals, this allows accumulation of cells with oncogenic mutations.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
60	377	320	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	5	Uncontrolled Hepatocyte Proliferation	The combination of impaired checkpoints, apoptosis resistance, chronic inflammation, and hepatocyte regeneration drives clonal expansion of transformed cells, eventually leading to HCC development.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
61	387	330	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	3	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			sorafenib	CHEBI:50924	sorafenib		"{""preferred_term"": ""sorafenib"", ""term"": {""id"": ""CHEBI:50924"", ""label"": ""sorafenib""}}"
62	406	372	14	Ainhum	Ainhum.yaml	phenotypes	2	Autoamputation of digits	Progressive constriction leads to autoamputation of the affected digit.	phenotype_term	Autoamputation of digits	HP:0007460	Autoamputation of digits	located_in	0	phenotype_term.located_in	located_in			toe	UBERON:0001466	pedal digit		"{""preferred_term"": ""toe"", ""term"": {""id"": ""UBERON:0001466"", ""label"": ""pedal digit""}}"
63	409	376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	excision	NCIT:C15232	Excision		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}"
64	438	400	15	Akinetopsia	Akinetopsia.yaml	treatments	1	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			carbamazepine	CHEBI:3387	carbamazepine		"{""preferred_term"": ""carbamazepine"", ""term"": {""id"": ""CHEBI:3387"", ""label"": ""carbamazepine""}}"
65	451	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	biological_processes[0]	Protein misfolding	GO:0006457	protein folding	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
66	463	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	biological_processes[0]	Protein hyperphosphorylation	GO:0006468	protein phosphorylation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
67	472	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	biological_processes[0]	Neurotransmitter release	GO:0007269	neurotransmitter secretion	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
68	473	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	biological_processes[1]	Synaptic plasticity	GO:0048167	regulation of synaptic plasticity	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
69	483	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	biological_processes[0]	Immune activation	GO:0002253	activation of immune response	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
70	484	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	biological_processes[1]	Cytokine production	GO:0001816	cytokine production	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
71	491	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	biological_processes[0]	Free radical production	GO:1903409	reactive oxygen species biosynthetic process	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
72	492	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	biological_processes[1]	Antioxidant defense	GO:0006979	response to oxidative stress	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
73	501	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	biological_processes[0]	Blood-brain barrier regulation	GO:1905603	regulation of blood-brain barrier permeability	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
74	502	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	biological_processes[1]	Cerebral blood flow	GO:0120275	cerebral blood circulation	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
75	509	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	biological_processes[0]	Autophagy	GO:0006914	autophagy	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
76	510	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	biological_processes[1]	Lysosomal degradation	GO:0007041	lysosomal transport	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
77	511	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	biological_processes[2]	Protein catabolic process	GO:0030163	protein catabolic process	modifier	0	biological_processes[2].modifier	modifier						DECREASED	"""DECREASED"""
78	557	486	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	pathophysiology	0	PAX-FOXO1 Fusion Oncogene	The t(2;13) or t(1;13) translocations fuse the DNA-binding domain of PAX3 or PAX7 with the transactivation domain of FOXO1. The resulting fusion protein functions as a potent aberrant transcription factor that activates PAX target genes to supraphysiological levels, driving proliferation while blocking terminal myogenic differentiation.	biological_processes[0]	positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
79	559	487	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	pathophysiology	1	Blocked Myogenic Differentiation	PAX-FOXO1 fusion protein blocks the normal myogenic differentiation program by interfering with MYOD1 and myogenin function. Tumor cells express early myogenic markers (desmin, myogenin) but fail to complete differentiation into mature skeletal muscle, remaining in a proliferative progenitor state.	biological_processes[0]	cell differentiation	GO:0030154	cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
80	560	488	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	pathophysiology	2	Aberrant Cell Proliferation	PAX-FOXO1 activates genes promoting cell cycle progression and survival, including MYCN, which is commonly amplified in ARMS. The fusion protein also suppresses apoptosis through multiple mechanisms, contributing to tumor aggressiveness.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
81	565	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
82	565	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"
83	565	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
84	573	500	21	Alzheimer's Disease	Alzheimers_Disease.yaml	pathophysiology	0	Amyloid-Beta Plaque Formation	"Extracellular accumulation of amyloid-beta (Aβ) peptides into senile plaques. Aβ is produced through sequential cleavage of amyloid precursor protein (APP) by β-secretase and γ-secretase. Soluble oligomeric forms of Aβ are toxic to synapses and interfere with synaptic plasticity and memory formation.
"	biological_processes[0]	amyloid precursor protein catabolic process	GO:0042987	amyloid precursor protein catabolic process	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
85	713	653	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	1	Oxidative Stress and DNA Damage	Arsenic generates reactive oxygen species (ROS) through multiple mechanisms including mitochondrial dysfunction and NADPH oxidase activation. ROS cause oxidative DNA damage including 8-oxoguanine formation, DNA strand breaks, and chromosomal aberrations. Unlike classic genotoxins, arsenic does not form direct DNA adducts but induces damage through indirect mechanisms.	biological_processes[0]	DNA damage response	GO:0006974	DNA damage response	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
86	714	654	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	2	Epigenetic Dysregulation	Arsenic causes global DNA hypomethylation while inducing promoter-specific hypermethylation of tumor suppressor genes. This occurs partly through competition for methyl groups (arsenic methylation depletes SAM) and altered DNMT activity. Histone modifications and miRNA expression are also affected, contributing to aberrant gene expression patterns.	biological_processes[0]	DNA methylation	GO:0006306	DNA methylation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
87	715	655	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	3	Impaired DNA Repair	Arsenic inhibits multiple DNA repair pathways including nucleotide excision repair, base excision repair, and mismatch repair. It inhibits zinc finger proteins involved in repair by displacing zinc. PARP-1, XPA, and other repair factors are direct targets. This repair deficiency synergizes with oxidative damage to promote mutagenesis.	biological_processes[0]	DNA repair	GO:0006281	DNA repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
88	716	656	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	4	Tumor Suppressor Gene Silencing	Arsenic-induced promoter hypermethylation silences tumor suppressor genes including p16INK4A, RASSF1A, and p53. This epigenetic silencing contributes to cell cycle dysregulation and resistance to apoptosis without requiring genetic mutation.	biological_processes[0]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
89	717	657	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	5	Genomic Instability	The combination of oxidative DNA damage, impaired repair, and aberrant mitotic spindle function leads to genomic instability, aneuploidy, and chromosomal aberrations. Arsenic disrupts spindle assembly by targeting tubulin and centrosome function.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
90	719	658	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	6	Uncontrolled Cell Proliferation	Combined effects of epigenetic silencing, genomic instability, and constitutive growth signaling drive proliferation of transformed cells in target organs. The skin, lung, and bladder are particularly susceptible due to their exposure to arsenic and its metabolites.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
91	859	835	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	pathophysiology	0	BRAF V600E Constitutive Activation	The BRAF V600E mutation causes constitutive activation of the RAF kinase by mimicking the phosphorylated active state. This results in ligand-independent activation of the MAPK pathway driving thyroid follicular cell proliferation and dedifferentiation.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
92	861	836	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	pathophysiology	1	MEK-ERK Pathway Hyperactivation	Mutant BRAF constitutively phosphorylates and activates MEK1/2, leading to sustained ERK1/2 activation. This drives uncontrolled proliferation and is the rationale for combined BRAF/MEK inhibition therapy.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
93	862	837	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	pathophysiology	2	Thyroid Dedifferentiation	BRAF V600E-driven MAPK activation suppresses expression of thyroid differentiation genes including NIS (sodium-iodide symporter), leading to radioiodine refractoriness. This loss of differentiation is associated with more aggressive disease behavior.	biological_processes[0]	cell differentiation	GO:0030154	cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
94	868	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			dabrafenib	CHEBI:75045	dabrafenib		"{""preferred_term"": ""dabrafenib"", ""term"": {""id"": ""CHEBI:75045"", ""label"": ""dabrafenib""}}"
95	868	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			trametinib	CHEBI:75998	trametinib		"{""preferred_term"": ""trametinib"", ""term"": {""id"": ""CHEBI:75998"", ""label"": ""trametinib""}}"
96	871	844	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	3	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"
97	875	853	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	0	BRAF V600E Constitutive Activation	The V600E mutation substitutes glutamic acid for valine at position 600 in the activation segment of BRAF kinase. This mimics phosphorylation-induced activation, locking BRAF in an active conformation. The mutant kinase signals constitutively through MEK and ERK without upstream RAS activation.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
98	876	854	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	1	Uncontrolled MAPK Pathway Signaling	Constitutive BRAF V600E activation leads to continuous phosphorylation of MEK1/2, which phosphorylates ERK1/2. Activated ERK translocates to the nucleus and drives expression of genes promoting cell proliferation, survival, and invasion. This signaling is independent of growth factor receptor activation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
99	877	854	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	1	Uncontrolled MAPK Pathway Signaling	Constitutive BRAF V600E activation leads to continuous phosphorylation of MEK1/2, which phosphorylates ERK1/2. Activated ERK translocates to the nucleus and drives expression of genes promoting cell proliferation, survival, and invasion. This signaling is independent of growth factor receptor activation.	biological_processes[1]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
100	879	856	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	3	EGFR Feedback Reactivation	Unlike melanoma, colorectal cancer cells have high EGFR expression. When BRAF is inhibited, relief of ERK-mediated negative feedback leads to rapid EGFR reactivation, which signals through RAS and CRAF to restore MAPK pathway activity. This explains why BRAF inhibitor monotherapy fails in colorectal cancer but works in melanoma.	biological_processes[0]	ERBB signaling pathway	GO:0038127	ERBB signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
101	891	871	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	0	BRAF V600E Oncogenic Mutation	The BRAF V600E mutation substitutes glutamic acid for valine at codon 600 in the activation segment. This mimics phosphorylation, causing constitutive kinase activation. V600E signals as a monomer independent of upstream RAS, unlike wild-type BRAF which requires RAS-mediated dimerization.	biological_processes[0]	protein kinase activity	GO:0004672	protein kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
102	892	872	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive MAPK Pathway Activation	BRAF V600E constitutively phosphorylates and activates MEK1/2, which in turn phosphorylates and activates ERK1/2. This leads to uncontrolled proliferation and survival signaling. The lack of dependence on upstream RAS makes the tumor exquisitely sensitive to BRAF inhibition.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
103	893	873	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	2	Cell Proliferation and Survival	Constitutive ERK signaling drives expression of cyclin D1 and other cell cycle genes, promoting uncontrolled proliferation. ERK also inhibits pro-apoptotic proteins through phosphorylation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
104	894	874	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	3	BRAF/MEK Inhibitor Resistance	Resistance to BRAF/MEK inhibition can develop through MAPK pathway reactivation (BRAF amplification, MEK mutations, NRAS mutations), bypass pathway activation (PI3K-AKT), or histologic transformation. Combination BRAF+MEK inhibition delays resistance compared to BRAF inhibitor monotherapy.	biological_processes[0]	response to drug	GO:0042493	response to drug	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
105	906	887	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	0	BRAF V600 Oncogenic Mutation	BRAF V600 mutations, predominantly V600E and V600K, result in substitution of the valine residue in the activation loop of the BRAF kinase. This removes an autoinhibitory mechanism, causing constitutive kinase activity independent of upstream RAS signaling. The mutant BRAF signals as a monomer, unlike wild-type BRAF which requires dimerization for activation.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
106	907	888	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	1	Constitutive MAPK Pathway Activation	Mutant BRAF continuously phosphorylates and activates MEK1/2, which in turn activates ERK1/2. This constitutive MAPK signaling drives expression of genes promoting cell cycle progression, survival, and proliferation. The pathway operates independently of growth factor stimulation.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
107	908	888	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	1	Constitutive MAPK Pathway Activation	Mutant BRAF continuously phosphorylates and activates MEK1/2, which in turn activates ERK1/2. This constitutive MAPK signaling drives expression of genes promoting cell cycle progression, survival, and proliferation. The pathway operates independently of growth factor stimulation.	biological_processes[1]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
108	911	889	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	2	Uncontrolled Melanocyte Proliferation	Constitutive MAPK signaling drives melanocyte proliferation through ERK-mediated phosphorylation and stabilization of transcription factors controlling cell cycle progression, including upregulation of cyclin D1 and suppression of cell cycle inhibitors such as p27.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
109	912	890	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	3	Apoptosis Resistance	BRAF V600 signaling promotes melanoma cell survival through multiple anti-apoptotic mechanisms, including upregulation of BCL2 family members and suppression of pro-apoptotic BIM. This contributes to tumor persistence and therapy resistance.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
110	921	903	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	pathophysiology	0	Homologous Recombination Repair Deficiency	Loss of functional BRCA1 or BRCA2 impairs homologous recombination repair (HRR), the high-fidelity pathway for repairing DNA double-strand breaks. This leads to accumulation of genomic instability and reliance on error-prone repair pathways.	biological_processes[0]	double-strand break repair via homologous recombination	GO:0000724	double-strand break repair via homologous recombination	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
111	923	904	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	pathophysiology	1	Genomic Instability	HRR deficiency leads to genomic instability characterized by chromosomal rearrangements, copy number alterations, and mutational signatures typical of BRCA deficiency. This drives aggressive tumor behavior but also creates therapeutic vulnerabilities.	biological_processes[0]	DNA repair	GO:0006281	DNA repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
112	924	905	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	pathophysiology	2	Synthetic Lethality with PARP Inhibition	PARP enzymes are essential for single-strand break repair. In HRR-deficient cells, PARP inhibition causes accumulation of double-strand breaks that cannot be repaired, leading to synthetic lethality and selective tumor cell death.	biological_processes[0]	single-strand break repair	GO:0000012	single-strand break repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
113	928	909	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	0	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			olaparib	CHEBI:83766	olaparib		"{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}"
114	930	910	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	1	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			rucaparib	CHEBI:134689	rucaparib		"{""preferred_term"": ""rucaparib"", ""term"": {""id"": ""CHEBI:134689"", ""label"": ""rucaparib""}}"
115	991	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	broad spectrum antibiotic	NCIT:C2883	Broad Spectrum Antibiotic		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}"
116	994	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	anti-infective agent	NCIT:C28254	Anti-Infective Agent		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anti-infective agent"", ""term"": {""id"": ""NCIT:C28254"", ""label"": ""Anti-Infective Agent""}}}"
117	997	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	dexamethasone	NCIT:C620	Dexamethasone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dexamethasone"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Dexamethasone""}}}"
118	1000	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term	supportive care	MAXO:0000950	supportive care	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	fluid therapy	NCIT:C15693	Fluid Replacement Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""fluid therapy"", ""term"": {""id"": ""NCIT:C15693"", ""label"": ""Fluid Replacement Therapy""}}}"
119	1000	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term	supportive care	MAXO:0000950	supportive care	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	anticonvulsant agent	NCIT:C614	Anticonvulsant Agent		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anticonvulsant agent"", ""term"": {""id"": ""NCIT:C614"", ""label"": ""Anticonvulsant Agent""}}}"
120	1005	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	treatment_term	vaccination	MAXO:0001017	vaccination	qualifier	0	treatment_term.qualifiers[0]	immunologic factor	NCIT:C307	Immunologic Factor	vaccine	NCIT:C15260	Vaccine		"{""predicate"": {""preferred_term"": ""immunologic factor"", ""term"": {""id"": ""NCIT:C307"", ""label"": ""Immunologic Factor""}}, ""value"": {""preferred_term"": ""vaccine"", ""term"": {""id"": ""NCIT:C15260"", ""label"": ""Vaccine""}}}"
121	1048	1011	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	0	PTCH1 Loss of Function	PTCH1 (Patched 1) encodes a transmembrane receptor that normally suppresses Smoothened (SMO) in the absence of Hedgehog ligand. Loss-of-function mutations in PTCH1 release SMO from inhibition, resulting in constitutive Hedgehog pathway activation. PTCH1 mutations occur in approximately 70% of sporadic BCCs and are the germline cause of Gorlin syndrome.	biological_processes[0]	smoothened signaling pathway	GO:0007224	smoothened signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
122	1051	1012	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	1	SMO Activating Mutations	Smoothened (SMO) is a G-protein coupled receptor-like protein that transduces Hedgehog signal. Activating mutations in SMO, though less common than PTCH1 loss, render SMO constitutively active regardless of PTCH1 status. Some SMO mutations confer resistance to vismodegib.	biological_processes[0]	smoothened signaling pathway	GO:0007224	smoothened signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
123	1052	1013	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	2	Constitutive Hedgehog Pathway Activation	Loss of PTCH1 or activating SMO mutations result in constitutive activation of the Hedgehog signaling cascade. Active SMO translocates to the primary cilium and promotes activation of GLI transcription factors (GLI1, GLI2), which drive expression of target genes promoting proliferation and survival.	biological_processes[0]	smoothened signaling pathway	GO:0007224	smoothened signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
124	1053	1014	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	3	GLI Transcription Factor Activation	Active Hedgehog signaling promotes GLI transcription factor processing and nuclear translocation. GLI1 and GLI2 activate transcription of target genes including PTCH1, GLI1 (positive feedback), cyclin D1, MYC, and BCL2, promoting proliferation and survival of basal cells.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
125	1056	1015	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	4	Uncontrolled Basal Cell Proliferation	Constitutive Hedgehog signaling drives proliferation of basal cells through GLI-mediated transcription of cell cycle regulators, leading to tumor formation. The proliferating cells maintain a basal cell phenotype with peripheral palisading characteristic of BCC histology.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
126	1060	1019	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vismodegib	CHEBI:66903	vismodegib		"{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}"
127	1180	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			prednisone	CHEBI:8382	prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}"
128	1180	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			azathioprine	CHEBI:2948	azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}"
129	1183	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			mycophenolate mofetil	CHEBI:8764	mycophenolate mofetil		"{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""CHEBI:8764"", ""label"": ""mycophenolate mofetil""}}"
130	1183	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			azathioprine	CHEBI:2948	azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}"
131	1186	1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			pirfenidone	CHEBI:32016	pirfenidone		"{""preferred_term"": ""pirfenidone"", ""term"": {""id"": ""CHEBI:32016"", ""label"": ""pirfenidone""}}"
132	1188	1170	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	3	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			nintedanib	CHEBI:85164	nintedanib		"{""preferred_term"": ""nintedanib"", ""term"": {""id"": ""CHEBI:85164"", ""label"": ""nintedanib""}}"
133	1235	1226	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	0	MYC Translocation and Oncogene Activation	The hallmark of Burkitt lymphoma is translocation of the MYC oncogene on chromosome 8 to an immunoglobulin locus, most commonly t(8;14)(q24;q32) involving the IGH locus, or less commonly t(2;8) or t(8;22) involving light chain loci. This places MYC under control of immunoglobulin enhancers, resulting in constitutive MYC overexpression.	biological_processes[0]	positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
134	1237	1227	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	1	Uncontrolled B-Cell Proliferation	MYC is a master transcriptional regulator of cell growth and proliferation. Constitutive MYC expression drives continuous cell cycle progression, resulting in one of the fastest doubling times of any human tumor (approximately 24 hours). The proliferation fraction approaches 100% (Ki-67 staining).	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
135	1238	1228	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	2	Apoptosis Resistance	While MYC normally sensitizes cells to apoptosis, Burkitt lymphoma cells acquire mutations or alterations that counteract MYC-induced apoptosis. TP53 mutations occur in approximately 30% of cases. EBV-encoded EBNA1 and EBERs provide additional survival signals in EBV-positive cases.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
136	1239	1229	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	3	High-Grade Malignancy with Rapid Tumor Growth	The combination of constitutive MYC-driven proliferation and apoptosis resistance results in rapidly growing tumors. The high proliferation rate paradoxically makes the tumor highly sensitive to chemotherapy, contributing to excellent cure rates with intensive treatment.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
137	1248	1238	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	1	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			rituximab	CHEBI:64357	rituximab		"{""preferred_term"": ""rituximab"", ""term"": {""id"": ""CHEBI:64357"", ""label"": ""rituximab""}}"
138	1358	1371	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	0	E6 Oncoprotein-Mediated p53 Degradation	The HPV E6 oncoprotein binds to the cellular E3 ubiquitin ligase E6AP and targets p53 for proteasomal degradation. Loss of p53 function eliminates DNA damage checkpoints, allows cells with genomic instability to survive, and prevents apoptosis of infected cells.	biological_processes[0]	proteasome-mediated ubiquitin-dependent protein catabolic process	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
139	1359	1371	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	0	E6 Oncoprotein-Mediated p53 Degradation	The HPV E6 oncoprotein binds to the cellular E3 ubiquitin ligase E6AP and targets p53 for proteasomal degradation. Loss of p53 function eliminates DNA damage checkpoints, allows cells with genomic instability to survive, and prevents apoptosis of infected cells.	biological_processes[1]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
140	1361	1372	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	1	E7 Oncoprotein-Mediated pRB Inactivation	The HPV E7 oncoprotein binds to and inactivates the retinoblastoma protein (pRB), releasing E2F transcription factors to drive uncontrolled cell cycle progression. E7 also targets pRB family members p107 and p130, and destabilizes pRB through proteasomal degradation.	biological_processes[0]	G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
141	1362	1372	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	1	E7 Oncoprotein-Mediated pRB Inactivation	The HPV E7 oncoprotein binds to and inactivates the retinoblastoma protein (pRB), releasing E2F transcription factors to drive uncontrolled cell cycle progression. E7 also targets pRB family members p107 and p130, and destabilizes pRB through proteasomal degradation.	biological_processes[1]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
142	1364	1374	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	3	Cervical Intraepithelial Neoplasia Progression	HPV infection induces a spectrum of preinvasive lesions graded as CIN1, CIN2, and CIN3 (carcinoma in situ). Low-grade lesions (CIN1) often regress, while high-grade lesions (CIN2/3) have significant risk of progression to invasive carcinoma over 10-20 years if untreated.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
143	1371	1382	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	3	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
144	1460	1528	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	0	B-cell Receptor Signaling Dysregulation	CLL cells exhibit constitutive B-cell receptor (BCR) signaling, either through autonomous signaling or antigen-driven activation. This chronic BCR stimulation activates downstream kinases including BTK, PI3K, and SYK, driving proliferation and survival. BCR signaling intensity correlates with clinical aggressiveness.	biological_processes[0]	B cell activation	GO:0042113	B cell activation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
145	1461	1529	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	1	BTK Pathway Activation	Bruton tyrosine kinase (BTK) is essential for BCR signaling and CLL cell survival. BTK activation promotes NF-kB signaling, cell adhesion, and tissue homing. BTK inhibitors disrupt these signals, mobilizing CLL cells from protective tissue microenvironments and inducing apoptosis.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
146	1465	1531	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	3	NF-kB Activation and Survival	NF-kB transcription factors are constitutively activated in CLL and promote expression of anti-apoptotic genes including BCL2, MCL1, and XIAP. This contributes to the apoptosis resistance characteristic of CLL cells.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
147	1475	1541	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	0	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ibrutinib	CHEBI:76612	ibrutinib		"{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}"
148	1477	1542	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			acalabrutinib	CHEBI:167707	acalabrutinib		"{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}"
149	1479	1543	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	2	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"
150	1481	1544	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	3	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cyclophosphamide	CHEBI:4027	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}"
151	1490	1551	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	1	Constitutive Tyrosine Kinase Activation	The BCR-ABL1 fusion protein exhibits constitutive tyrosine kinase activity, bypassing normal growth factor regulation. This activates multiple downstream signaling cascades including RAS-MAPK, PI3K-AKT, and JAK-STAT pathways, promoting cell proliferation and survival.	biological_processes[0]	protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
152	1491	1551	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	1	Constitutive Tyrosine Kinase Activation	The BCR-ABL1 fusion protein exhibits constitutive tyrosine kinase activity, bypassing normal growth factor regulation. This activates multiple downstream signaling cascades including RAS-MAPK, PI3K-AKT, and JAK-STAT pathways, promoting cell proliferation and survival.	biological_processes[1]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
153	1495	1552	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	2	Uncontrolled Myeloid Proliferation	BCR-ABL1 signaling drives excessive proliferation of myeloid progenitor cells, leading to marked expansion of the granulocytic lineage. The bone marrow becomes hypercellular with a massively expanded myeloid compartment.	biological_processes[0]	myeloid cell homeostasis	GO:0002262	myeloid cell homeostasis	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
154	1496	1553	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	3	Apoptosis Resistance	BCR-ABL1 activates anti-apoptotic pathways, particularly through PI3K-AKT signaling and upregulation of BCL2 family members. This confers resistance to programmed cell death, allowing accumulation of leukemic cells.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
155	1497	1554	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	4	Genomic Instability and Disease Progression	BCR-ABL1 induces genomic instability through reactive oxygen species generation and impaired DNA repair. This promotes acquisition of additional mutations and chromosomal abnormalities, driving progression from chronic phase to blast crisis.	biological_processes[0]	DNA repair	GO:0006281	DNA repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
156	1505	1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
157	1507	1566	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	1	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			dasatinib	CHEBI:49375	dasatinib		"{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}"
158	1509	1567	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	2	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			nilotinib	CHEBI:52172	nilotinib		"{""preferred_term"": ""nilotinib"", ""term"": {""id"": ""CHEBI:52172"", ""label"": ""nilotinib""}}"
159	1511	1568	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	3	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ponatinib	CHEBI:78543	ponatinib		"{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}"
160	1597	1652	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	0	VHL Tumor Suppressor Inactivation	Biallelic VHL loss is the initiating event in ccRCC. The VHL protein normally targets HIF-α subunits for ubiquitin-mediated degradation under normoxic conditions. Without functional VHL, HIF-α accumulates and constitutively activates hypoxia response genes.	biological_processes[0]	cellular response to hypoxia	GO:0071456	cellular response to hypoxia	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
161	1598	1652	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	0	VHL Tumor Suppressor Inactivation	Biallelic VHL loss is the initiating event in ccRCC. The VHL protein normally targets HIF-α subunits for ubiquitin-mediated degradation under normoxic conditions. Without functional VHL, HIF-α accumulates and constitutively activates hypoxia response genes.	biological_processes[1]	proteasome-mediated ubiquitin-dependent protein catabolic process	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
162	1600	1653	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	1	HIF-2α Stabilization	Without VHL-mediated degradation, HIF-2α protein accumulates in the cytoplasm and translocates to the nucleus where it dimerizes with HIF-1β (ARNT) to form an active transcription factor. HIF-2α is the critical HIF isoform in ccRCC.	biological_processes[0]	protein stabilization	GO:0050821	protein stabilization	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
163	1601	1654	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	2	VEGF-Driven Angiogenesis	HIF-2α transcriptionally activates VEGF (vascular endothelial growth factor), driving tumor neovascularization. The resulting hypervascular phenotype is characteristic of ccRCC and the basis for VEGFR-targeted therapy.	biological_processes[0]	angiogenesis	GO:0001525	angiogenesis	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
164	1602	1654	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	2	VEGF-Driven Angiogenesis	HIF-2α transcriptionally activates VEGF (vascular endothelial growth factor), driving tumor neovascularization. The resulting hypervascular phenotype is characteristic of ccRCC and the basis for VEGFR-targeted therapy.	biological_processes[1]	vascular endothelial growth factor receptor signaling pathway	GO:0048010	vascular endothelial growth factor receptor signaling pathway	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
165	1603	1655	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	3	Growth Factor Pathway Activation	HIF-2α activates transcription of growth-promoting genes including TGF-α (which activates EGFR signaling) and cyclin D1 (which promotes cell cycle progression). This drives tumor cell proliferation independent of angiogenesis.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
166	1604	1656	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	4	Epigenetic Dysregulation	Secondary mutations in chromatin remodeling genes (PBRM1 in 40%, BAP1 in 15%, SETD2 in 15%) contribute to ccRCC progression. BAP1 mutations are associated with higher grade tumors and worse prognosis compared to PBRM1 mutations. These mutations cooperate with VHL loss to drive tumor evolution.	biological_processes[0]	chromatin remodeling	GO:0006338	chromatin remodeling	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
167	1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			sunitinib	CHEBI:38940	sunitinib		"{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}"
168	1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			pazopanib	CHEBI:71219	pazopanib		"{""preferred_term"": ""pazopanib"", ""term"": {""id"": ""CHEBI:71219"", ""label"": ""pazopanib""}}"
169	1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			axitinib	CHEBI:66910	axitinib		"{""preferred_term"": ""axitinib"", ""term"": {""id"": ""CHEBI:66910"", ""label"": ""axitinib""}}"
170	1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			cabozantinib	CHEBI:72317	cabozantinib		"{""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}"
171	1619	1672	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	pathophysiology	0	EWSR1-ATF1 Fusion Oncogene	The t(12;22)(q13;q12) translocation fuses the EWSR1 gene on chromosome 22 with ATF1 on chromosome 12 in approximately 90% of cases. The fusion protein functions as an aberrant transcription factor that constitutively activates MITF (microphthalmia-associated transcription factor), driving melanocytic differentiation and survival programs.	biological_processes[0]	positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
172	1621	1673	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	pathophysiology	1	MITF Activation	EWSR1-ATF1 directly activates transcription of MITF, the master transcription factor of melanocyte lineage. MITF in turn activates genes involved in melanogenesis, cell survival, and proliferation. This explains the melanocytic phenotype despite soft tissue origin.	biological_processes[0]	regulation of gene expression	GO:0010468	regulation of gene expression	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
173	1622	1674	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	pathophysiology	2	Melanocytic Differentiation	Downstream of MITF activation, CCS cells express melanocytic markers including S100, HMB45, Melan-A, and tyrosinase. Melanin pigment may be present. However, unlike melanoma, CCS lacks UV-induced mutations and BRAF/NRAS alterations typical of cutaneous melanoma.	biological_processes[0]	cell differentiation	GO:0030154	cell differentiation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
174	1630	1682	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	3	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
175	1647	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	route of administration	NCIT:C38114	Route of Administration	oral route of administration	NCIT:C38288	Oral Route of Administration		"{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}"
176	1647	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	vancomycin	NCIT:C288	vancomycin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vancomycin"", ""term"": {""id"": ""NCIT:C288"", ""label"": ""vancomycin""}}}"
177	1652	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	route of administration	NCIT:C38114	Route of Administration	oral route of administration	NCIT:C38288	Oral Route of Administration		"{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}"
178	1652	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	fidaxomicin	NCIT:C95509	fidaxomicin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""fidaxomicin"", ""term"": {""id"": ""NCIT:C95509"", ""label"": ""fidaxomicin""}}}"
179	1657	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	treatment_term	fecal microbiota transplantation	MAXO:0000748	fecal microbiota transplantation	qualifier	0	treatment_term.qualifiers[0]	clinical course	NCIT:C28008	Clinical Course	recurrent disease	MONDO:0700096	recurrent disease		"{""predicate"": {""preferred_term"": ""clinical course"", ""term"": {""id"": ""NCIT:C28008"", ""label"": ""Clinical Course""}}, ""value"": {""preferred_term"": ""recurrent disease"", ""term"": {""id"": ""MONDO:0700096"", ""label"": ""recurrent disease""}}}"
180	1660	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	bezlotoxumab	NCIT:C121379	Bezlotoxumab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bezlotoxumab"", ""term"": {""id"": ""NCIT:C121379"", ""label"": ""Bezlotoxumab""}}}"
181	1689	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term	topical corticosteroid therapy	MAXO:0001553	topical corticosteroid therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	budesonide	NCIT:C66948	Budesonide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""budesonide"", ""term"": {""id"": ""NCIT:C66948"", ""label"": ""Budesonide""}}}"
182	1689	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term	topical corticosteroid therapy	MAXO:0001553	topical corticosteroid therapy	qualifier	1	treatment_term.qualifiers[1]	route of administration	NCIT:C38114	Route of Administration	gastrointestinal route	NCIT:C38295	Gastrointestinal Route of Administration		"{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""gastrointestinal route"", ""term"": {""id"": ""NCIT:C38295"", ""label"": ""Gastrointestinal Route of Administration""}}}"
183	1694	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	azathioprine	NCIT:C620	Azathioprine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Azathioprine""}}}"
184	1697	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF-α Therapy	"TNF-α inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF-α-mediated inflammation and immune activation.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	infliximab	NCIT:C2894	Infliximab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C2894"", ""label"": ""Infliximab""}}}"
185	1700	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	tacrolimus	NCIT:C2982	Tacrolimus		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tacrolimus"", ""term"": {""id"": ""NCIT:C2982"", ""label"": ""Tacrolimus""}}}"
186	1704	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	treatment_term	nutritional supplementation	MAXO:0000106	nutritional supplementation	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	iron supplement	NCIT:C2346	Iron Supplement		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""iron supplement"", ""term"": {""id"": ""NCIT:C2346"", ""label"": ""Iron Supplement""}}}"
187	1716	1753	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	0	CBF Transcription Factor Complex Disruption	The core binding factor complex consists of RUNX1 (alpha subunit) and CBFB (beta subunit). RUNX1 binds DNA while CBFB stabilizes this binding. Both t(8;21) and inv(16) produce fusion proteins that dominantly inhibit normal CBF function, disrupting transcription of genes essential for myeloid differentiation.	biological_processes[0]	myeloid cell differentiation	GO:0030099	myeloid cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
188	1718	1754	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	1	Differentiation Block at Myeloid Stage	CBF fusion proteins recruit corepressor complexes including HDACs and NCoR, converting CBF from a transcriptional activator to a repressor. This silences differentiation genes while partially preserving some myeloid identity, resulting in blasts with partial maturation features.	biological_processes[0]	granulocyte differentiation	GO:0030851	granulocyte differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
189	1719	1755	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	2	Self-Renewal Maintenance	CBF fusion proteins maintain expression of self-renewal genes while blocking differentiation. Additional mutations, particularly in receptor tyrosine kinases (KIT, FLT3), provide proliferative signals that cooperate with CBF fusions to cause overt leukemia.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
190	1924	1990	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	pathophysiology	0	COL1A1-PDGFB Fusion Oncogene	The t(17;22)(q22;q13) translocation or supernumerary ring chromosomes containing material from chromosomes 17 and 22 fuse the COL1A1 gene to PDGFB. This places PDGFB under control of the highly active COL1A1 promoter, resulting in constitutive expression of a functional PDGF-BB growth factor.	biological_processes[0]	positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
191	1926	1991	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	pathophysiology	1	Autocrine PDGFR Signaling	Tumor cells secrete mature PDGF-BB which binds to PDGFR-beta on the same or neighboring tumor cells, creating an autocrine/paracrine growth loop. PDGFR-beta activation drives proliferation through the MAPK and PI3K pathways. This signaling can be blocked by imatinib.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
192	1927	1992	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	pathophysiology	2	Sustained Proliferation	Constitutive PDGFR-beta signaling drives sustained proliferation of dermal fibroblasts. The infiltrative growth pattern with finger-like projections into subcutaneous fat explains the high local recurrence rate after incomplete excision.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
193	1932	1997	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	1	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
194	1948	2023	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	pathophysiology	0	EWSR1-WT1 Fusion Oncogene	The t(11;22)(p13;q12) translocation fuses EWSR1 on chromosome 22 with WT1 on chromosome 11. The resulting fusion protein contains the potent transcriptional activation domain of EWSR1 fused to the zinc finger DNA-binding domain of WT1. This chimeric transcription factor activates aberrant gene expression programs including PDGFA.	biological_processes[0]	positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
195	1950	2024	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	pathophysiology	1	PDGFA Activation	EWSR1-WT1 directly activates transcription of PDGFA, creating an autocrine growth loop that stimulates tumor cell proliferation and may contribute to the characteristic desmoplastic stromal reaction.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
196	1951	2025	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	pathophysiology	2	Multiphenotypic Differentiation	DSRCT displays a unique multiphenotypic immunophenotype with co-expression of epithelial (cytokeratin, EMA), mesenchymal (vimentin, desmin), and neural (NSE) markers. This reflects the aberrant differentiation program driven by EWSR1-WT1.	biological_processes[0]	cell differentiation	GO:0030154	cell differentiation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
197	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
198	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
199	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
200	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"
201	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	4	treatment_term.therapeutic_agent[4]	therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"
202	1980	2063	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	1	BCL2 Overexpression and Apoptosis Resistance	BCL2 translocation t(14;18) occurs in approximately 30% of GCB-DLBCL, placing BCL2 under immunoglobulin enhancer control. Resulting BCL2 overexpression blocks the mitochondrial apoptosis pathway, allowing survival of cells that would normally die in the germinal center.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
203	1981	2064	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	2	MYC-Driven Proliferation	MYC rearrangements occur in 10-15% of DLBCL, most commonly with IGH but also with non-immunoglobulin partners. MYC overexpression drives cellular proliferation and metabolism. When combined with BCL2 rearrangement (double-hit lymphoma), creates highly aggressive disease.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
204	1983	2065	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	3	NF-kB Constitutive Activation	ABC-DLBCL shows constitutive NF-kB activation through various mechanisms including BCR signaling mutations (CD79A/B), CARD11 mutations, MYD88 L265P mutation, or A20 deletion. NF-kB promotes survival and contributes to the aggressive behavior of ABC subtype.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
205	1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cyclophosphamide	CHEBI:4027	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}"
206	1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
207	1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
208	1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			prednisone	CHEBI:8382	prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}"
209	2070	2174	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	1	Epigenetic Reprogramming and CIMP-High Phenotype	EBV-associated gastric cancer displays the most extreme CpG island methylator phenotype (CIMP) of any cancer type. EBV-encoded proteins, particularly LMP2A, induce aberrant DNA methylation leading to silencing of tumor suppressor genes including CDKN2A (p16), CDH1 (E-cadherin), and MLH1. This epigenetic reprogramming is a hallmark feature distinguishing EBV-positive from EBV-negative gastric cancers.	biological_processes[0]	DNA methylation	GO:0006306	DNA methylation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
210	2071	2175	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	PIK3CA mutations occur in approximately 80% of EBV-positive gastric cancers, the highest frequency of any gastric cancer subtype. Combined with LMP2A signaling which activates PI3K through mimicry of B-cell receptor signaling, this leads to constitutive AKT activation promoting cell survival and proliferation.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
211	2072	2176	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	3	Tumor Suppressor Gene Silencing	Promoter hypermethylation silences multiple tumor suppressor genes. CDKN2A (p16INK4A) silencing removes G1/S checkpoint control. CDH1 (E-cadherin) silencing promotes epithelial-mesenchymal transition. Unlike other gastric cancer subtypes, TP53 mutations are rare in EBV-positive tumors.	biological_processes[0]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
212	2074	2177	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	4	Uncontrolled Cell Proliferation	Combined effects of PI3K-AKT activation, tumor suppressor silencing, and viral oncogene expression drive uncontrolled proliferation of infected gastric epithelial cells, leading to tumor formation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
213	2086	2194	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	0	EGFR Oncogenic Mutations	Activating EGFR mutations occur in the tyrosine kinase domain and cause constitutive receptor activation independent of ligand binding. Mutations alter the ATP-binding pocket, favoring the active kinase conformation and enhancing sensitivity to ATP-competitive TKIs.	biological_processes[0]	epidermal growth factor receptor signaling pathway	GO:0007173	epidermal growth factor receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
214	2087	2195	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive EGFR Signaling	Mutant EGFR is constitutively phosphorylated, activating downstream signaling cascades including RAS-RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The tumor becomes dependent on (addicted to) EGFR signaling for survival.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
215	2088	2195	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive EGFR Signaling	Mutant EGFR is constitutively phosphorylated, activating downstream signaling cascades including RAS-RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The tumor becomes dependent on (addicted to) EGFR signaling for survival.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
216	2089	2196	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	2	Oncogene Addiction	EGFR-mutant tumors exhibit oncogene addiction, with survival critically dependent on continued EGFR signaling. EGFR inhibition leads to rapid tumor regression through induction of apoptosis and cell cycle arrest. This creates the therapeutic window for TKI therapy.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
217	2090	2197	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	3	TKI Resistance Mechanisms	Resistance to EGFR TKIs develops through multiple mechanisms: secondary EGFR mutations (T790M, C797S), bypass pathway activation (MET amplification, HER2 amplification), and histologic transformation (small cell or squamous). Understanding resistance guides sequential therapy selection.	biological_processes[0]	response to drug	GO:0042493	response to drug	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
218	2102	2215	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	0	Estrogen Receptor Activation	ER+ breast cancer is driven by estrogen-dependent activation of the estrogen receptor alpha (ERα), a nuclear hormone receptor that functions as a ligand-activated transcription factor. Estrogen binding induces receptor dimerization, DNA binding, and transcriptional activation of target genes.	biological_processes[0]	intracellular estrogen receptor signaling pathway	GO:0030520	intracellular estrogen receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
219	2103	2216	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	1	Estrogen-Driven Transcription	Activated ERα binds estrogen response elements (EREs) in target gene promoters, recruiting coactivators and driving transcription of genes promoting cell cycle progression (CCND1), survival (BCL2), and growth factor signaling (IGF1R, EGFR). This creates estrogen-dependent tumor growth.	biological_processes[0]	positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
220	2104	2217	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	2	Cell Cycle Progression	ER signaling drives expression of cyclin D1 (CCND1), which complexes with CDK4/6 to phosphorylate Rb and promote G1-S transition. This creates the therapeutic rationale for CDK4/6 inhibitors in ER+ breast cancer.	biological_processes[0]	G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
221	2105	2217	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	2	Cell Cycle Progression	ER signaling drives expression of cyclin D1 (CCND1), which complexes with CDK4/6 to phosphorylate Rb and promote G1-S transition. This creates the therapeutic rationale for CDK4/6 inhibitors in ER+ breast cancer.	biological_processes[1]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
222	2213	2348	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	pathophysiology	0	Loss of Heterozygosity at 11p15	Loss of heterozygosity (LOH) at chromosome 11p15.5 is the hallmark genetic event in ERMS, occurring in approximately 80% of cases. This region contains the imprinted IGF2 gene, and LOH results in loss of the maternal allele with duplication of the paternal allele, leading to biallelic IGF2 expression and growth factor pathway activation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
223	2214	2349	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	pathophysiology	1	IGF2 Overexpression	Loss of imprinting at 11p15 results in biallelic expression of IGF2, leading to autocrine and paracrine growth stimulation through IGF1R signaling. This promotes cell proliferation and survival in ERMS cells.	biological_processes[0]	regulation of cell population proliferation	GO:0042127	regulation of cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
224	2215	2350	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	pathophysiology	2	RAS Pathway Activation	Activating mutations in RAS pathway genes (NRAS, KRAS, HRAS) occur in approximately 35% of ERMS cases. FGFR4 mutations occur in 7-10% of cases. These mutations drive proliferation through MAPK and PI3K pathway activation.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
225	2220	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
226	2220	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"
227	2220	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
228	2274	2452	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL converge on constitutive JAK-STAT signaling activation. JAK2 V617F directly activates the kinase; CALR mutations cause aberrant activation of MPL receptor; MPL mutations cause constitutive thrombopoietin receptor activation.	biological_processes[0]	JAK-STAT signaling pathway	GO:0007259	JAK-STAT cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
229	2276	2453	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	pathophysiology	1	Enhanced Megakaryopoiesis	Constitutive JAK-STAT signaling drives increased megakaryocyte proliferation and maturation. Unlike myelofibrosis, megakaryocytes in ET are large and mature without significant atypia or clustering.	biological_processes[0]	megakaryocyte differentiation	GO:0030219	megakaryocyte differentiation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
230	2277	2454	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	pathophysiology	2	Platelet Dysfunction and Thrombosis Risk	Despite elevated platelet counts, thrombosis risk is multifactorial and involves platelet activation, leukocyte-platelet interactions, and endothelial dysfunction. Paradoxically, extreme thrombocytosis (>1,000,000/uL) may cause acquired von Willebrand disease and bleeding.	biological_processes[0]	platelet activation	GO:0030168	platelet activation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
231	2285	2462	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	1	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"
232	2287	2463	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	2	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			anagrelide	CHEBI:142290	anagrelide		"{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}"
233	2292	2470	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	pathophysiology	0	EWS-FLI1 Fusion Oncogene	The t(11;22)(q24;q12) translocation fuses the EWS gene (EWSR1) on chromosome 22 with the FLI1 gene on chromosome 11. The resulting EWS-FLI1 protein functions as an aberrant transcription factor that activates proliferative genes and represses differentiation programs. This single genetic event is the primary driver of Ewing sarcoma.	biological_processes[0]	positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
234	2294	2471	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	pathophysiology	1	Aberrant Transcriptional Regulation	EWS-FLI1 binds to GGAA microsatellite repeats throughout the genome, creating de novo enhancers that activate oncogenic target genes including NKX2-2, NR0B1, and IGF1. This abnormal enhancer activity reprograms cell identity and drives the Ewing sarcoma phenotype.	biological_processes[0]	regulation of gene expression	GO:0010468	regulation of gene expression	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
235	2295	2472	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	pathophysiology	2	Blocked Differentiation	EWS-FLI1 represses genes required for mesenchymal differentiation, maintaining cells in a proliferative, undifferentiated state. The cell of origin remains debated but may be a neural crest-derived mesenchymal progenitor.	biological_processes[0]	cell differentiation	GO:0030154	cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
236	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vincristine	CHEBI:27375	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}"
237	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
238	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
239	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"
240	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	4	treatment_term.therapeutic_agent[4]	therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"
241	2312	2489	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	0	FGFR2 Fusion and Constitutive Activation	FGFR2 fusions join the FGFR2 kinase domain to various partner genes (BICC1, PPHLN1, AHCYL1, and others). Partner genes typically provide oligomerization domains that cause ligand-independent FGFR2 dimerization and constitutive kinase activation. This drives oncogenic signaling through multiple downstream pathways.	biological_processes[0]	fibroblast growth factor receptor signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
242	2314	2490	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	1	MAPK Pathway Activation	FGFR2 activation leads to recruitment of adaptor proteins (FRS2, GRB2) that activate RAS and the downstream MAPK cascade. This drives transcription of genes promoting cell proliferation.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
243	2315	2491	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	FGFR2 signaling activates PI3K through adaptor proteins, leading to AKT phosphorylation. This promotes cell survival and resistance to apoptosis. PI3K pathway activation may contribute to resistance to FGFR inhibitors.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
244	2316	2493	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	4	Enhanced Cell Proliferation	Combined activation of MAPK, PI3K-AKT, and PLCgamma pathways drives enhanced cell proliferation. FGFR2 fusion-positive tumors are dependent on FGFR2 signaling, making them vulnerable to FGFR inhibition.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
245	2331	2511	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	pathophysiology	0	FGFR3 Constitutive Activation	Activating mutations in FGFR3 cause ligand-independent receptor dimerization and autophosphorylation. The most common mutations affect cysteine residues in the extracellular domain, creating aberrant disulfide bonds that constitutively activate the receptor.	biological_processes[0]	fibroblast growth factor receptor signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
246	2333	2512	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	pathophysiology	1	RAS-MAPK Pathway Activation	FGFR3 activation stimulates the RAS-RAF-MEK-ERK signaling cascade through adaptor proteins FRS2 and GRB2. This drives uncontrolled urothelial cell proliferation and is a major effector of FGFR-mediated transformation.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
247	2334	2513	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	FGFR3 activation recruits PI3K and activates the PI3K-AKT-mTOR signaling pathway, promoting urothelial cell survival and resistance to apoptosis.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
248	2361	2554	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	0	FLT3 Receptor Constitutive Activation	FLT3 is a class III receptor tyrosine kinase normally involved in hematopoietic progenitor cell survival and proliferation. FLT3-ITD mutations cause ligand-independent receptor dimerization and constitutive autophosphorylation. FLT3-TKD mutations stabilize the active kinase conformation. Both result in aberrant downstream signaling.	biological_processes[0]	protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
249	2363	2555	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	1	STAT5 Hyperactivation	FLT3-ITD mutations preferentially activate STAT5 signaling compared to wild-type FLT3 or TKD mutations. Phosphorylated STAT5 translocates to the nucleus and activates transcription of anti-apoptotic genes (BCL-XL, PIM1) and cell cycle regulators, promoting leukemic cell survival and proliferation.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
250	2364	2556	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	2	RAS-MAPK Pathway Activation	FLT3 signaling activates the RAS-RAF-MEK-ERK cascade, driving cell proliferation and survival. This pathway is critical for the proliferative advantage of FLT3-mutated leukemic cells.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
251	2365	2557	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	3	Apoptosis Resistance	FLT3-ITD-mediated STAT5 activation upregulates anti-apoptotic proteins including BCL-XL, MCL-1, and PIM kinases. This confers resistance to apoptosis and contributes to the aggressive clinical behavior of FLT3-ITD AML.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
252	2368	2558	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	4	Uncontrolled Myeloblast Proliferation	The combined effects of enhanced survival signaling and cell cycle promotion lead to accumulation of immature myeloid blasts in the bone marrow and blood, replacing normal hematopoiesis.	biological_processes[0]	myeloid cell differentiation	GO:0030099	myeloid cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
253	2375	2565	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	0	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			midostaurin	CHEBI:63452	midostaurin		"{""preferred_term"": ""midostaurin"", ""term"": {""id"": ""CHEBI:63452"", ""label"": ""midostaurin""}}"
254	2377	2566	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	1	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			gilteritinib	CHEBI:145372	gilteritinib		"{""preferred_term"": ""gilteritinib"", ""term"": {""id"": ""CHEBI:145372"", ""label"": ""gilteritinib""}}"
255	2419	2600	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	1	Wnt/β-Catenin Pathway Activation	APC normally functions in the destruction complex (with Axin, GSK3β, CK1) to phosphorylate β-catenin, targeting it for ubiquitination and proteasomal degradation. Loss of APC allows β-catenin to accumulate, translocate to the nucleus, and activate Wnt target genes driving proliferation.	biological_processes[0]	Wnt signaling pathway	GO:0016055	Wnt signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
256	2421	2601	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	2	Uncontrolled Intestinal Epithelial Proliferation	Nuclear β-catenin activates TCF/LEF transcription factors, driving expression of Wnt target genes including MYC, CCND1 (cyclin D1), and others that promote cell cycle progression. This results in uncontrolled proliferation of intestinal crypt cells, forming adenomatous polyps.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
257	2424	2603	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	4	Colorectal Cancer Progression	Adenomas acquire additional mutations in KRAS, TP53, SMAD4, and other genes through the adenoma-carcinoma sequence. In FAP, the large number of adenomas makes it virtually certain that at least one will progress to invasive adenocarcinoma without intervention.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
258	2788	2954	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	0	CagA-Mediated Oncogenic Signaling	The cagA gene encodes the CagA oncoprotein, a major H. pylori virulence factor injected into host cells via a type IV secretion system. CagA is phosphorylated by host kinases and activates SHP-2, disrupting cell polarity, promoting proliferation, and inhibiting apoptosis. CagA-positive strains confer higher cancer risk.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
259	2789	2954	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	0	CagA-Mediated Oncogenic Signaling	The cagA gene encodes the CagA oncoprotein, a major H. pylori virulence factor injected into host cells via a type IV secretion system. CagA is phosphorylated by host kinases and activates SHP-2, disrupting cell polarity, promoting proliferation, and inhibiting apoptosis. CagA-positive strains confer higher cancer risk.	biological_processes[1]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
260	2791	2955	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	1	VacA-Induced Cellular Damage	VacA (vacuolating cytotoxin A) is a pore-forming toxin that induces vacuolation, mitochondrial dysfunction, and apoptosis in epithelial cells. It also suppresses T cell function, allowing bacterial persistence. Different VacA alleles (s1/s2, m1/m2) confer different cancer risk.	biological_processes[0]	cellular response to cytotoxic stimulus	GO:0034620	cellular response to oxidative stress	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
261	2792	2956	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	2	Chronic Inflammation (Correa Cascade)	H. pylori induces chronic gastritis with infiltration of neutrophils, lymphocytes, and macrophages. Persistent inflammation generates reactive oxygen and nitrogen species that cause DNA damage. Over decades, this leads to atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately adenocarcinoma.	biological_processes[0]	inflammatory response	GO:0006954	inflammatory response	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
262	2793	2956	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	2	Chronic Inflammation (Correa Cascade)	H. pylori induces chronic gastritis with infiltration of neutrophils, lymphocytes, and macrophages. Persistent inflammation generates reactive oxygen and nitrogen species that cause DNA damage. Over decades, this leads to atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately adenocarcinoma.	biological_processes[1]	response to oxidative stress	GO:0006979	response to oxidative stress	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
263	2795	2957	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	3	CDH1/E-cadherin Inactivation	Loss of E-cadherin function through somatic mutation, promoter methylation, or loss of heterozygosity occurs in diffuse-type gastric cancer and some intestinal-type tumors. E-cadherin loss disrupts cell-cell adhesion and activates Wnt/beta-catenin signaling, promoting invasion.	biological_processes[0]	cell-cell adhesion	GO:0098609	cell-cell adhesion	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
264	2820	3006	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	Gain-of-function mutations in KIT result in constitutive receptor dimerization and kinase activation without ligand (stem cell factor) binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell proliferation and survival.	biological_processes[0]	receptor signaling protein tyrosine kinase activity	GO:0004716	receptor signaling protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
265	2821	3006	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	Gain-of-function mutations in KIT result in constitutive receptor dimerization and kinase activation without ligand (stem cell factor) binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell proliferation and survival.	biological_processes[1]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
266	2824	3007	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	1	PDGFRA Receptor Activation	PDGFRA mutations, particularly D842V in the activation loop, result in constitutive kinase activity. These mutations activate similar downstream pathways as KIT but show different drug sensitivity profiles.	biological_processes[0]	platelet-derived growth factor receptor signaling pathway	GO:0048008	platelet-derived growth factor receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
267	2825	3008	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	2	RAS-MAPK Pathway Activation	Constitutive KIT or PDGFRA activation drives the RAS-RAF-MEK-ERK signaling cascade, promoting cell proliferation. This pathway represents a potential therapeutic target when primary resistance to KIT/PDGFRA inhibitors occurs.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
268	2826	3009	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	3	PI3K-AKT Pathway Activation	Constitutive KIT or PDGFRA activation recruits PI3K and activates the PI3K-AKT-mTOR signaling cascade, promoting cell survival and resistance to apoptosis. This pathway cooperates with MAPK signaling to drive tumorigenesis.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
269	2832	3015	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	0	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
270	2834	3016	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	1	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			sunitinib	CHEBI:38940	sunitinib		"{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}"
271	2888	3130	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	0	TERT Promoter Activation	TERT promoter mutations (C228T or C250T) occur in approximately 80% of IDH-wildtype glioblastomas. These mutations create de novo ETS transcription factor binding sites, leading to TERT upregulation and telomerase reactivation. This enables unlimited replicative potential and is a defining molecular feature.	biological_processes[0]	telomere maintenance via telomerase	GO:0007004	telomere maintenance via telomerase	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
272	2890	3131	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	1	Chromosome 7 Gain and Chromosome 10 Loss	Combined gain of chromosome 7 (+7) and loss of chromosome 10 (-10) is a defining molecular feature of IDH-wildtype glioblastoma, present in over 90% of cases. Chromosome 7 gain amplifies EGFR and MET. Chromosome 10 loss deletes PTEN and other tumor suppressors.	biological_processes[0]	chromosome organization	GO:0051276	chromosome organization	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
273	2891	3132	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	2	EGFR/MET Pathway Activation	EGFR is amplified in 40-50% and MET in 5% of glioblastomas. EGFR amplification is often accompanied by EGFRvIII, a constitutively active deletion variant lacking exons 2-7. These alterations drive proliferation through RAS/RAF/MAPK and PI3K/AKT pathways.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
274	2892	3132	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	2	EGFR/MET Pathway Activation	EGFR is amplified in 40-50% and MET in 5% of glioblastomas. EGFR amplification is often accompanied by EGFRvIII, a constitutively active deletion variant lacking exons 2-7. These alterations drive proliferation through RAS/RAF/MAPK and PI3K/AKT pathways.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
275	2893	3133	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	3	PTEN Tumor Suppressor Loss	PTEN loss through chromosome 10 deletion, mutation, or epigenetic silencing occurs in 40-50% of glioblastomas. Loss of PTEN phosphatase activity leads to constitutive PI3K/AKT/mTOR pathway activation, promoting survival and growth.	biological_processes[0]	negative regulation of phosphatidylinositol 3-kinase signaling	GO:0014067	negative regulation of phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
276	2894	3134	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	4	PI3K/AKT/mTOR Pathway Hyperactivation	Constitutive PI3K/AKT/mTOR activation through EGFR amplification, PIK3CA mutation, or PTEN loss promotes cell survival, proliferation, metabolism, and angiogenesis. This pathway is active in nearly all glioblastomas.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
277	2895	3134	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	4	PI3K/AKT/mTOR Pathway Hyperactivation	Constitutive PI3K/AKT/mTOR activation through EGFR amplification, PIK3CA mutation, or PTEN loss promotes cell survival, proliferation, metabolism, and angiogenesis. This pathway is active in nearly all glioblastomas.	biological_processes[1]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
278	2896	3135	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	5	Unlimited Replicative Potential	Telomerase reactivation through TERT promoter mutations enables glioblastoma cells to bypass replicative senescence and achieve unlimited proliferative capacity, a hallmark of cancer.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
279	2898	3136	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	6	Uncontrolled Cell Proliferation	Multiple converging pathways (RTK signaling, PI3K/AKT/mTOR, cell cycle dysregulation) drive rapid proliferation characteristic of glioblastoma. High mitotic index and proliferation markers (Ki-67 often >20%) are typical.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
280	2939	3181	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	pathophysiology	0	PTCH1 Germline Mutations	PTCH1 encodes Patched 1, a 12-pass transmembrane receptor that normally suppresses Smoothened (SMO) in the absence of Hedgehog ligand. Germline heterozygous loss-of-function mutations in PTCH1 predispose to tumors following Knudson's two-hit model. Loss of the remaining wild-type allele in somatic cells leads to constitutive Hedgehog pathway activation and tumor development.	biological_processes[0]	smoothened signaling pathway	GO:0007224	smoothened signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
281	2940	3182	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	pathophysiology	1	SUFU Germline Mutations	A minority of Gorlin syndrome cases (approximately 5%) are caused by germline mutations in SUFU (Suppressor of Fused), which encodes a negative regulator of GLI transcription factors. SUFU mutations are associated with markedly higher risk of medulloblastoma (up to 20-fold higher) compared to PTCH1 mutations, with tumors typically occurring before age 3 years.	biological_processes[0]	negative regulation of smoothened signaling pathway	GO:0045879	negative regulation of smoothened signaling pathway	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
282	2941	3183	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	pathophysiology	2	Constitutive Hedgehog Pathway Activation	Loss of PTCH1 function or SUFU mutations result in constitutive activation of the Hedgehog signaling cascade. Without functional PTCH1, Smoothened is no longer suppressed and activates GLI transcription factors, driving expression of target genes involved in proliferation, survival, and developmental patterning.	biological_processes[0]	smoothened signaling pathway	GO:0007224	smoothened signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
283	2954	3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vismodegib	CHEBI:66903	vismodegib		"{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}"
284	3051	3331	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	0	H3 K27M Oncohistone Mutation	Lysine-to-methionine substitution at position 27 of histone H3 (K27M) occurs in H3F3A (encoding H3.3) or HIST1H3B/HIST1H3C (encoding H3.1). Despite being present in only 5-15% of total H3 molecules, the mutant histone acts as a dominant negative, sequestering and inhibiting the PRC2 complex.	biological_processes[0]	histone H3-K27 methylation	GO:0098532	histone H3-K27 methylation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
285	3055	3332	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	1	PRC2 Complex Inhibition and H3K27me3 Loss	The H3 K27M mutant histone binds to and inhibits EZH2, the catalytic subunit of PRC2, which normally trimethylates H3K27. This results in global loss of H3K27me3, a repressive epigenetic mark, leading to aberrant gene activation and loss of cell identity.	biological_processes[0]	negative regulation of gene expression, epigenetic	GO:0045814	negative regulation of gene expression, epigenetic	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
286	3056	3333	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	2	Epigenetic Derepression and Aberrant Gene Activation	Global loss of H3K27me3 causes derepression of genes normally silenced during development, including proliferative and stemness genes. Paradoxically, some loci show retained or increased H3K27me3, suggesting complex redistribution rather than simple loss.	biological_processes[0]	gene expression	GO:0010467	gene expression	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
287	3057	3333	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	2	Epigenetic Derepression and Aberrant Gene Activation	Global loss of H3K27me3 causes derepression of genes normally silenced during development, including proliferative and stemness genes. Paradoxically, some loci show retained or increased H3K27me3, suggesting complex redistribution rather than simple loss.	biological_processes[1]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
288	3059	3334	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	3	Loss of Glial Differentiation	Epigenetic dysregulation prevents normal glial differentiation, maintaining cells in a proliferative, undifferentiated state. This contributes to the aggressive behavior and treatment resistance of these tumors.	biological_processes[0]	glial cell differentiation	GO:0010001	glial cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
289	3070	3347	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	0	ERBB2 Gene Amplification	HER2-positive breast cancer is driven by amplification of the ERBB2 gene on chromosome 17q12, resulting in overexpression of the HER2 receptor tyrosine kinase. Gene amplification typically results in 25-50 copies per cell, leading to massive receptor overexpression on the cell surface.	biological_processes[0]	ERBB2 signaling pathway	GO:0038128	ERBB2 signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
290	3071	3348	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	1	Constitutive Receptor Activation	Massive HER2 overexpression promotes spontaneous receptor homodimerization and heterodimerization with other ERBB family members (EGFR, HER3, HER4) without ligand binding. This constitutive activation drives downstream signaling cascades promoting proliferation, survival, and invasion.	biological_processes[0]	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
291	3072	3349	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	2	Downstream Oncogenic Signaling	Activated HER2 signals through PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways, promoting cell proliferation, survival, and resistance to apoptosis. HER2-HER3 heterodimers are particularly potent activators of the PI3K pathway.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
292	3073	3349	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	2	Downstream Oncogenic Signaling	Activated HER2 signals through PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways, promoting cell proliferation, survival, and resistance to apoptosis. HER2-HER3 heterodimers are particularly potent activators of the PI3K pathway.	biological_processes[1]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
293	3074	3350	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	3	Uncontrolled Proliferation	Constitutive HER2 signaling drives continuous cell cycle progression and resistance to apoptotic signals. HER2+ tumors are typically high grade with high proliferation indices (high Ki-67).	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
294	3085	3366	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	0	ERBB2 (HER2) Amplification and Overexpression	ERBB2 gene amplification leads to overexpression of the HER2 receptor tyrosine kinase on the cell surface. Amplified HER2 forms homodimers and heterodimers with other ERBB family members (particularly HER3), leading to ligand-independent receptor activation and downstream signaling.	biological_processes[0]	ERBB2 signaling pathway	GO:0038128	ERBB2 signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
295	3086	3367	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	1	MAPK Pathway Activation	HER2 receptor activation leads to recruitment of adaptor proteins (GRB2/SOS) that activate RAS, initiating the MAPK signaling cascade. This drives cell proliferation and survival. The MAPK pathway is a major effector of HER2 oncogenic signaling in colorectal cancer.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
296	3087	3368	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	HER2 heterodimerization with HER3 is particularly potent at activating PI3K signaling because HER3 contains multiple PI3K binding sites. This leads to AKT activation, promoting cell survival and resistance to apoptosis. PI3K pathway activation may contribute to resistance to HER2-targeted therapy.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
297	3089	3369	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	3	Enhanced Cell Proliferation	Combined MAPK and PI3K pathway activation drives enhanced cell proliferation through cyclin D1 induction and cell cycle progression. This leads to uncontrolled tumor growth dependent on HER2 signaling.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
298	3095	3375	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	0	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
299	3097	3376	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	1	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
300	3100	3378	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	3	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
301	3105	3386	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	0	ERBB2 (HER2) Amplification and Overexpression	ERBB2 gene amplification leads to overexpression of the HER2 receptor tyrosine kinase. High-level HER2 expression promotes constitutive receptor dimerization (particularly HER2 homodimers and HER2/HER3 heterodimers), leading to ligand-independent signaling. HER2 amplification is a driver event in gastric carcinogenesis.	biological_processes[0]	ERBB2 signaling pathway	GO:0038128	ERBB2 signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
302	3107	3387	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	1	MAPK Pathway Activation	HER2 receptor activation recruits GRB2/SOS adaptor proteins, activating RAS and the downstream MAPK cascade. This drives transcription of genes promoting cell proliferation, including cyclin D1 and MYC.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
303	3108	3388	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	HER2/HER3 heterodimerization is particularly effective at activating PI3K because HER3 contains six PI3K binding motifs. PI3K activation leads to AKT phosphorylation, promoting cell survival, protein synthesis through mTOR, and resistance to apoptosis. PI3K pathway alterations may confer resistance to HER2-targeted therapy.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
304	3109	3389	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	3	Enhanced Proliferation and Tumor Growth	Combined MAPK and PI3K/AKT pathway activation drives uncontrolled cell proliferation and tumor growth. HER2-positive tumors are dependent on HER2 signaling, making them vulnerable to HER2-targeted therapies.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
305	3117	3397	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	0	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
306	3120	3399	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	2	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
307	3153	3439	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	0	TP53 Mutation and Inactivation	TP53 mutations occur in greater than 80% of HPV-negative HNSCC, representing the most common genetic alteration. Mutations are typically missense mutations in the DNA-binding domain caused by tobacco carcinogen-induced DNA adducts. Loss of p53 function eliminates cell cycle checkpoints and DNA damage repair.	biological_processes[0]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
308	3154	3439	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	0	TP53 Mutation and Inactivation	TP53 mutations occur in greater than 80% of HPV-negative HNSCC, representing the most common genetic alteration. Mutations are typically missense mutations in the DNA-binding domain caused by tobacco carcinogen-induced DNA adducts. Loss of p53 function eliminates cell cycle checkpoints and DNA damage repair.	biological_processes[1]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
309	3157	3440	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	1	CDKN2A/p16 Inactivation	CDKN2A is inactivated by deletion, mutation, or promoter hypermethylation in approximately 60-70% of HPV-negative HNSCC. Loss of p16INK4a removes inhibition of CDK4/6, promoting cell cycle progression through the restriction point.	biological_processes[0]	negative regulation of G1/S transition	GO:0045786	negative regulation of G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
310	3158	3441	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	2	EGFR Overexpression and Signaling	EGFR is overexpressed in 80-90% of HNSCC and amplified in a subset. EGFR signaling activates RAS-MAPK and PI3K-AKT pathways, promoting proliferation, survival, and invasion. EGFR is a validated therapeutic target in HNSCC.	biological_processes[0]	epidermal growth factor receptor signaling pathway	GO:0007173	epidermal growth factor receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
311	3160	3442	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	3	NOTCH1 Inactivation	NOTCH1 loss-of-function mutations occur in approximately 15-20% of HPV-negative HNSCC. NOTCH signaling normally promotes squamous differentiation and growth arrest, functioning as a tumor suppressor in squamous epithelia.	biological_processes[0]	Notch signaling pathway	GO:0007219	Notch signaling pathway	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
312	3169	3451	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	1	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
313	3176	3463	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	0	E6-Mediated p53 Degradation	HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to target p53 for proteasomal degradation, eliminating DNA damage checkpoints and allowing survival of cells with genomic instability. Unlike HPV-negative HNSCC, TP53 mutations are rare in HPV-positive tumors.	biological_processes[0]	proteasome-mediated ubiquitin-dependent protein catabolic process	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
314	3177	3463	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	0	E6-Mediated p53 Degradation	HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to target p53 for proteasomal degradation, eliminating DNA damage checkpoints and allowing survival of cells with genomic instability. Unlike HPV-negative HNSCC, TP53 mutations are rare in HPV-positive tumors.	biological_processes[1]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
315	3179	3464	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	1	E7-Mediated pRB Inactivation	HPV E7 oncoprotein binds and degrades the retinoblastoma protein (pRB), releasing E2F transcription factors to drive S-phase entry. This causes compensatory overexpression of p16INK4a, which serves as a clinical biomarker for HPV-associated tumors.	biological_processes[0]	G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
316	3180	3464	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	1	E7-Mediated pRB Inactivation	HPV E7 oncoprotein binds and degrades the retinoblastoma protein (pRB), releasing E2F transcription factors to drive S-phase entry. This causes compensatory overexpression of p16INK4a, which serves as a clinical biomarker for HPV-associated tumors.	biological_processes[1]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
317	3182	3466	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	3	Immune Evasion	HPV-positive HNSCC evades immune surveillance through downregulation of antigen presentation and PD-L1 expression. However, these tumors are generally more immunogenic than HPV-negative HNSCC, contributing to better prognosis and response to immunotherapy.	biological_processes[0]	negative regulation of T cell mediated immunity	GO:0002710	negative regulation of T cell mediated immunity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
318	3189	3473	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	0	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
319	3293	3656	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	1	Telomere Dysfunction and Genomic Instability	Chronic hepatocyte proliferation leads to telomere shortening, causing genomic instability. TERT promoter mutations, which are the most common HCC mutations, reactivate telomerase to enable unlimited replication. This creates a checkpoint bypass allowing survival of genetically unstable cells.	biological_processes[0]	telomere maintenance	GO:0000723	telomere maintenance	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
320	3294	3657	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	2	Accumulation of Driver Mutations	Multiple driver genes are recurrently mutated in HCC, including TERT promoter (60%), TP53 (30%), CTNNB1 (30%), AXIN1 (10%), and ARID1A (10%). These mutations affect telomere maintenance, cell cycle control, WNT signaling, and chromatin remodeling.	biological_processes[0]	DNA repair	GO:0006281	DNA repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
321	3295	3658	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	3	WNT/Beta-Catenin Pathway Activation	Activating mutations in CTNNB1 (beta-catenin) or inactivating mutations in AXIN1 lead to constitutive WNT pathway activation. This drives cell proliferation and is associated with a distinct molecular subclass of HCC with specific clinical features including cholestasis and immune exclusion.	biological_processes[0]	Wnt signaling pathway	GO:0016055	Wnt signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
322	3296	3659	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	4	TP53 Pathway Inactivation	TP53 mutations are common in HCC, particularly in HBV-associated and aflatoxin-associated tumors. Loss of p53 function removes a critical checkpoint, allowing survival of cells with DNA damage and promoting genomic instability.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
323	3297	3660	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	5	Enhanced Hepatocyte Proliferation	Combined effects of telomerase reactivation, cell cycle checkpoint loss, and mitogenic signaling drive uncontrolled hepatocyte proliferation and tumor growth.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
324	3298	3661	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	6	Angiogenesis and VEGF Signaling	HCC is a highly vascular tumor dependent on angiogenesis. VEGF signaling promotes new blood vessel formation supplying the tumor. VEGF also has immunosuppressive effects, contributing to the immune-excluded microenvironment. This provides the rationale for anti-VEGF therapy in combination with immunotherapy.	biological_processes[0]	angiogenesis	GO:0001525	angiogenesis	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
325	3314	3683	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	pathophysiology	0	BRCA1/2 Tumor Suppressor Loss	Germline heterozygous BRCA1 or BRCA2 mutations result in one functional allele. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates BRCA function, initiating tumorigenesis. This follows Knudson's two-hit hypothesis for tumor suppressor gene inactivation.	biological_processes[0]	DNA repair	GO:0006281	DNA repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
326	3315	3684	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	pathophysiology	1	Homologous Recombination Deficiency	BRCA1 and BRCA2 are essential components of the homologous recombination (HR) pathway for error-free repair of DNA double-strand breaks. Loss of BRCA function forces cells to rely on error-prone repair pathways such as non-homologous end joining, leading to genomic instability.	biological_processes[0]	homologous recombination	GO:0035825	homologous recombination	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
327	3316	3685	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	pathophysiology	2	Genomic Instability	Loss of HR-mediated repair leads to accumulation of chromosomal aberrations, large-scale genomic rearrangements, and copy number alterations. This pattern of genomic instability, termed 'BRCAness' or homologous recombination deficiency (HRD), is characteristic of BRCA-deficient tumors and creates therapeutic vulnerability to PARP inhibitors.	biological_processes[0]	regulation of DNA damage checkpoint	GO:0010618	regulation of DNA damage checkpoint	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
328	3317	3686	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	pathophysiology	3	Tumor Development	Progressive accumulation of genomic alterations in BRCA-deficient cells leads to transformation and tumor development. The tissue specificity (breast, ovary) may relate to estrogen exposure and proliferative demands on these tissues, though the precise mechanisms remain incompletely understood.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
329	3325	3694	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	2	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			olaparib	CHEBI:83766	olaparib		"{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}"
330	3334	3723	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	0	Failure of Enteric Ganglion Cell Migration	Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.	cell_types[0]	enteric neuron	CL:0007011	enteric neuron	modifier	0	cell_types[0].modifier	modifier						ABSENT	"""ABSENT"""
331	3335	3723	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	0	Failure of Enteric Ganglion Cell Migration	Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.	biological_processes[0]	neural crest cell migration	GO:0001755	neural crest cell migration	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
332	3336	3723	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	0	Failure of Enteric Ganglion Cell Migration	Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.	biological_processes[1]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
333	3339	3724	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	1	Disrupted Enteric Nervous System Development	The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.	cell_types[0]	enteric neuron	CL:0007011	enteric neuron	modifier	0	cell_types[0].modifier	modifier						ABSENT	"""ABSENT"""
334	3340	3724	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	1	Disrupted Enteric Nervous System Development	The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.	biological_processes[0]	neuron differentiation	GO:0030182	neuron differentiation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
335	3341	3724	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	1	Disrupted Enteric Nervous System Development	The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.	biological_processes[1]	peristalsis	GO:0030432	peristalsis	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
336	3533	3896	163	Hypochondroplasia	Hypochondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling (mild)	"The FGFR3 N540K mutation causes constitutive activation of the receptor, but with less severe effects than the G380R mutation in achondroplasia. This results in moderately impaired endochondral ossification with reduced chondrocyte proliferation in the growth plate, leading to mild short stature.
"	gene	FGFR3	hgnc:3690	FGFR3	modifier	0	gene.modifier	modifier						INCREASED	"""INCREASED"""
337	3546	3912	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	1	2-HG Accumulation and Dioxygenase Inhibition	2-HG is structurally similar to alpha-ketoglutarate and competitively inhibits alpha-ketoglutarate-dependent dioxygenases. Key targets include TET2 DNA demethylases, Jumonji-domain histone demethylases, and prolyl hydroxylases. This disrupts normal epigenetic regulation and hypoxia responses.	biological_processes[0]	DNA demethylation	GO:0080111	DNA demethylation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
338	3547	3913	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	2	DNA Hypermethylation	Inhibition of TET2 by 2-HG impairs the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, disrupting active DNA demethylation. This causes hypermethylation at gene promoters, silencing differentiation genes and contributing to the leukemic phenotype.	biological_processes[0]	myeloid cell differentiation	GO:0030099	myeloid cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
339	3548	3914	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	3	Histone Methylation Dysregulation	2-HG inhibits Jumonji-domain histone demethylases that remove methyl groups from lysine residues on histones. This causes accumulation of repressive histone marks and altered gene expression patterns contributing to leukemogenesis.	biological_processes[0]	histone demethylation	GO:0016577	histone demethylation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
340	3556	3921	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	0	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ivosidenib	CHEBI:145430	ivosidenib		"{""preferred_term"": ""ivosidenib"", ""term"": {""id"": ""CHEBI:145430"", ""label"": ""ivosidenib""}}"
341	3558	3922	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	1	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			enasidenib	CHEBI:145374	enasidenib		"{""preferred_term"": ""enasidenib"", ""term"": {""id"": ""CHEBI:145374"", ""label"": ""enasidenib""}}"
342	3560	3923	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	2	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"
343	3566	3936	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	Heterozygous mutations in IDH1 (R132H most common, >90%) or IDH2 (R172) confer neomorphic enzyme activity, converting alpha-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (2-HG). This occurs as an early clonal event in gliomagenesis.	biological_processes[0]	tricarboxylic acid cycle	GO:0006099	tricarboxylic acid cycle	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
344	3568	3937	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	1	2-HG Accumulation and Epigenetic Dysregulation	D-2-hydroxyglutarate competitively inhibits alpha-ketoglutarate-dependent dioxygenases including TET2 (DNA demethylation) and Jumonji-domain histone demethylases. This results in global DNA hypermethylation (G-CIMP phenotype) and histone hypermethylation, blocking cellular differentiation.	biological_processes[0]	DNA methylation	GO:0006306	DNA methylation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
345	3569	3937	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	1	2-HG Accumulation and Epigenetic Dysregulation	D-2-hydroxyglutarate competitively inhibits alpha-ketoglutarate-dependent dioxygenases including TET2 (DNA demethylation) and Jumonji-domain histone demethylases. This results in global DNA hypermethylation (G-CIMP phenotype) and histone hypermethylation, blocking cellular differentiation.	biological_processes[1]	cell differentiation	GO:0030154	cell differentiation	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
346	3571	3938	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	2	Blocked Glial Differentiation	Epigenetic dysregulation caused by 2-HG prevents normal glial differentiation programs, maintaining cells in a proliferative progenitor-like state. This contributes to tumor formation but also underlies the better prognosis compared to IDH-wildtype tumors due to retained differentiation potential.	biological_processes[0]	glial cell differentiation	GO:0010001	glial cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
347	3582	3955	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	IDH1 R132 or IDH2 R140/R172 mutations are neomorphic, conferring a new enzymatic function. Instead of converting isocitrate to alpha-ketoglutarate (aKG), mutant IDH converts aKG to the oncometabolite D-2-hydroxyglutarate (2-HG). 2-HG accumulates to millimolar concentrations in tumor cells.	biological_processes[0]	isocitrate dehydrogenase (NADP+) activity	GO:0004450	isocitrate dehydrogenase (NADP+) activity	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
348	3584	3957	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	pathophysiology	2	Epigenetic Dysregulation and DNA Hypermethylation	2-HG inhibition of TET2 blocks conversion of 5-methylcytosine to 5-hydroxymethylcytosine, causing DNA hypermethylation. This CpG island methylator phenotype (CIMP) silences tumor suppressor genes and differentiation programs, contributing to the block in cellular differentiation characteristic of IDH-mutant tumors.	biological_processes[0]	DNA methylation	GO:0006306	DNA methylation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
349	3585	3959	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	pathophysiology	4	Differentiation Block and Tumor Growth	Combined epigenetic alterations block normal cholangiocyte differentiation, maintaining cells in a progenitor-like state with proliferative capacity. This promotes tumor growth while the cells retain sensitivity to IDH inhibition, which can restore differentiation programs.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
350	3598	3980	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	Heterozygous IDH1 R132 or IDH2 R172 mutations produce D-2-hydroxyglutarate (2-HG), an oncometabolite causing epigenetic dysregulation through inhibition of alpha-ketoglutarate-dependent dioxygenases. This is an early clonal event shared with IDH-mutant astrocytomas.	biological_processes[0]	tricarboxylic acid cycle	GO:0006099	tricarboxylic acid cycle	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
351	3600	3981	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	1	1p/19q Codeletion	The 1p/19q codeletion results from an unbalanced translocation t(1;19)(q10;p10) occurring early in tumorigenesis. This leads to loss of tumor suppressor genes including CIC on 19q and FUBP1 on 1p. The codeletion is associated with oligodendroglial differentiation and exceptional chemosensitivity.	biological_processes[0]	chromosome organization	GO:0051276	chromosome organization	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
352	3601	3982	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	2	G-CIMP Hypermethylation Phenotype	Glioma CpG island methylator phenotype (G-CIMP) results from 2-HG-mediated inhibition of TET enzymes and histone demethylases. This leads to widespread promoter hypermethylation, altered gene expression, and blocked differentiation. G-CIMP is associated with favorable prognosis.	biological_processes[0]	DNA methylation	GO:0006306	DNA methylation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
353	3602	3983	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	3	CIC/FUBP1 Tumor Suppressor Loss	CIC (Capicua) on 19q13 is mutated in approximately 70% of oligodendrogliomas. FUBP1 on 1p31 is mutated in approximately 30%. These mutations cooperate with IDH mutation and 1p/19q codeletion to drive oligodendroglioma formation.	biological_processes[0]	negative regulation of cell population proliferation	GO:0008285	negative regulation of cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
354	3604	3984	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	4	Oligodendroglial Tumorigenesis	The combination of IDH mutation, 1p/19q codeletion, and CIC/FUBP1 mutations drives oligodendroglioma formation. These tumors retain oligodendroglial differentiation markers and maintain sensitivity to DNA-damaging agents, likely due to intact DNA damage response pathways.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
355	3634	4028	170	Infectious Disease	Infectious_Disease.yaml	pathophysiology	1	Host Genetic Susceptibility and Immune Response	Host genetic factors and immune response pathways influence progression from exposure to mild or severe infection and determine disease outcomes.	biological_processes[0]	immune response	GO:0006955	immune response	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
356	3690	4114	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	KIT mutations, most commonly in exons 11, 13, and 17, result in constitutive receptor activation independent of stem cell factor (SCF) ligand binding. Mutations may cause ligand-independent dimerization, altered kinase domain conformation, or loss of autoinhibitory mechanisms, leading to persistent downstream signaling.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
357	3691	4115	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	1	MAPK Pathway Activation	Activated KIT recruits adapter proteins that engage RAS-MAPK signaling, driving melanocyte proliferation through ERK-mediated transcriptional programs promoting cell cycle progression.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
358	3692	4116	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	KIT activates PI3K through recruitment and phosphorylation of adapter proteins. Subsequent AKT activation promotes cell survival through inhibition of pro-apoptotic proteins and activation of mTOR signaling.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
359	3694	4117	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	3	Uncontrolled Melanocyte Proliferation	Constitutive KIT signaling through MAPK and PI3K pathways drives abnormal melanocyte proliferation in acral and mucosal sites, leading to tumor formation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
360	3695	4118	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	4	Cell Survival and Anti-Apoptosis	PI3K-AKT activation downstream of KIT promotes melanoma cell survival through phosphorylation-mediated inactivation of pro-apoptotic proteins and activation of survival pathways.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
361	3698	4121	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	0	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
362	3705	4133	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	0	KRAS G12C Oncogenic Mutation	The KRAS G12C mutation substitutes cysteine for glycine at codon 12, impairing GTPase activity and trapping KRAS in the active GTP-bound state. However, unlike other KRAS mutations, G12C retains some GTPase activity, cycling between active (GTP-bound) and inactive (GDP-bound) states. This cycling creates a therapeutic window for covalent inhibitors that bind the mutant cysteine in the GDP-bound state.	biological_processes[0]	small GTPase mediated signal transduction	GO:0007264	small GTPase mediated signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
363	3706	4134	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive RAS Signaling	Mutant KRAS drives constitutive activation of downstream effector pathways including RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The MAPK pathway is the predominant driver of oncogenic phenotypes in KRAS-mutant NSCLC.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
364	3707	4134	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive RAS Signaling	Mutant KRAS drives constitutive activation of downstream effector pathways including RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The MAPK pathway is the predominant driver of oncogenic phenotypes in KRAS-mutant NSCLC.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
365	3708	4135	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	2	Cell Proliferation and Survival	Constitutive KRAS signaling promotes uncontrolled cell proliferation through ERK-mediated transcription of cell cycle genes and survival through AKT-mediated inhibition of apoptosis.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
366	3709	4136	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	3	KRAS G12C Inhibitor Resistance	Resistance to KRAS G12C inhibitors develops through multiple mechanisms: secondary KRAS mutations (Y96C, R68S, H95D/Q/R), KRAS amplification, bypass pathway activation (MET, EGFR, FGFR, PI3K), and histologic transformation. Adaptive feedback through RTK reactivation (EGFR, FGFR, SHP2) is common.	biological_processes[0]	response to drug	GO:0042493	response to drug	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
367	3722	4155	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	1	vFLIP-Mediated NF-kappaB Activation	Viral FLICE inhibitory protein (vFLIP) constitutively activates NF-kappaB signaling by interacting with IKK complex. This promotes cell survival, inflammation, and cytokine production. vFLIP also inhibits caspase-8-mediated apoptosis, providing resistance to death receptor-induced cell death.	biological_processes[0]	positive regulation of NF-kappaB transcription factor activity	GO:0051092	positive regulation of NF-kappaB transcription factor activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
368	3723	4156	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	2	vCyclin-Mediated Cell Cycle Dysregulation	Viral cyclin (vCyclin) forms active complexes with CDK6 that are resistant to inhibition by p16INK4A, p21, and p27. This drives cells through G1/S checkpoint regardless of normal growth regulatory signals, contributing to uncontrolled proliferation.	biological_processes[0]	G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
369	3724	4157	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	3	vGPCR-Mediated Angiogenic Signaling	The viral G protein-coupled receptor (vGPCR) is expressed during lytic reactivation and activates multiple signaling pathways in a ligand-independent manner, including VEGF production and MAPK activation. vGPCR is highly oncogenic and promotes the angiogenic, inflammatory microenvironment characteristic of KS lesions.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
370	3725	4158	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	4	Apoptosis Resistance and Cell Survival	Multiple viral genes cooperate to prevent apoptosis: vFLIP inhibits caspase-8 and activates NF-kappaB; LANA inhibits p53; vBCL-2 mimics cellular BCL-2. This multi-layered apoptosis resistance enables survival and accumulation of infected cells.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
371	3726	4159	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	5	Uncontrolled Cell Proliferation	Combined effects of vCyclin, LANA-mediated Rb inhibition, and growth factor signaling drive spindle cell proliferation, forming the characteristic KS lesions.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
372	3728	4160	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	6	Angiogenic Proliferation	KS lesions are highly vascular due to vGPCR-induced VEGF and inflammatory cytokine production. The aberrant angiogenesis creates the characteristic red-purple appearance and contributes to edema and hemorrhage.	biological_processes[0]	angiogenesis	GO:0001525	angiogenesis	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
373	3735	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
374	3735	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			paclitaxel	CHEBI:45863	paclitaxel		"{""preferred_term"": ""paclitaxel"", ""term"": {""id"": ""CHEBI:45863"", ""label"": ""paclitaxel""}}"
375	3890	4336	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	0	Failed foregut partitioning	Abnormal separation of the anterior foregut permits persistent communication between airway and esophagus.	biological_processes[0]	digestive tract development	GO:0048565	digestive tract development	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
376	3891	4336	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	0	Failed foregut partitioning	Abnormal separation of the anterior foregut permits persistent communication between airway and esophagus.	biological_processes[1]	respiratory system development	GO:0060541	respiratory system development	modifier	0	biological_processes[1].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
377	3892	4337	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	1	Disrupted BMP4 signaling during larynx development	Disruption of BMP4 signaling perturbs laryngeal development and is associated with laryngeal cleft in a mouse model.	biological_processes[0]	BMP signaling pathway	GO:0030509	BMP signaling pathway	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
378	3893	4337	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	1	Disrupted BMP4 signaling during larynx development	Disruption of BMP4 signaling perturbs laryngeal development and is associated with laryngeal cleft in a mouse model.	biological_processes[1]	larynx development	GO:0120224	larynx development	modifier	0	biological_processes[1].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
379	3898	4339	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	3	Foregut maldevelopment during respiratory and digestive tract development	Disrupted foregut development underlies formation of the cleft.	biological_processes[0]	digestive tract development	GO:0048565	digestive tract development	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
380	3899	4339	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	3	Foregut maldevelopment during respiratory and digestive tract development	Disrupted foregut development underlies formation of the cleft.	biological_processes[1]	respiratory system development	GO:0060541	respiratory system development	modifier	0	biological_processes[1].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
381	3915	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	laser surgery	NCIT:C15268	Laser Surgery		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}"
382	3918	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	laser surgery	NCIT:C15268	Laser Surgery		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}"
383	3918	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	carbon dioxide	NCIT:C65288	Carbon Dioxide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""carbon dioxide"", ""term"": {""id"": ""NCIT:C65288"", ""label"": ""Carbon Dioxide""}}}"
384	3923	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	hyaluronic acid	CHEBI:16336	hyaluronic acid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""hyaluronic acid"", ""term"": {""id"": ""CHEBI:16336"", ""label"": ""hyaluronic acid""}}}"
385	3926	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	endoscopic procedure	NCIT:C16546	Endoscopic Procedure		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""NCIT:C16546"", ""label"": ""Endoscopic Procedure""}}}"
386	3942	4381	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	0	TP53 Tumor Suppressor Loss	Germline heterozygous TP53 mutations result in haploinsufficiency for p53 function. Somatic loss or inactivation of the remaining wild-type allele (second hit) eliminates p53 tumor suppressor activity, removing a critical checkpoint against malignant transformation.	biological_processes[0]	signal transduction by p53 class mediator	GO:0072331	signal transduction by p53 class mediator	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
387	3943	4382	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	1	Loss of DNA Damage Response	p53 is a master regulator of the DNA damage response. Upon detecting DNA damage, p53 activates transcription of genes involved in cell cycle arrest, DNA repair, and apoptosis. Loss of p53 function eliminates this critical surveillance mechanism.	biological_processes[0]	DNA damage response, signal transduction by p53 class mediator	GO:0030330	DNA damage response, signal transduction by p53 class mediator	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
388	3944	4383	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	2	Loss of Cell Cycle Checkpoint Control	p53 induces G1 arrest in response to DNA damage by activating p21 (CDKN1A) transcription, which inhibits cyclin-dependent kinases. Without p53, cells with damaged DNA continue through the cell cycle, replicating mutations.	biological_processes[0]	G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
389	3945	4384	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	3	Impaired Apoptosis	p53 promotes apoptosis through transcriptional activation of pro-apoptotic genes (BAX, PUMA, NOXA) and repression of anti-apoptotic BCL2. Loss of p53 allows damaged and potentially transformed cells to survive and proliferate.	biological_processes[0]	intrinsic apoptotic signaling pathway by p53 class mediator	GO:0072332	intrinsic apoptotic signaling pathway by p53 class mediator	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
390	3946	4384	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	3	Impaired Apoptosis	p53 promotes apoptosis through transcriptional activation of pro-apoptotic genes (BAX, PUMA, NOXA) and repression of anti-apoptotic BCL2. Loss of p53 allows damaged and potentially transformed cells to survive and proliferate.	biological_processes[1]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
391	3947	4385	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	4	Genomic Instability	Loss of p53-mediated checkpoints and DNA repair coordination leads to progressive accumulation of genomic alterations including point mutations, chromosomal rearrangements, and aneuploidy. This genomic instability accelerates tumor development and drives cancer heterogeneity.	biological_processes[0]	DNA repair	GO:0006281	DNA repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
392	3948	4386	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	5	Tumor Development	The combination of impaired DNA damage response, loss of cell cycle checkpoints, defective apoptosis, and genomic instability creates a permissive environment for tumor development. Different tissues vary in susceptibility, explaining the characteristic cancer spectrum of LFS.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
393	4055	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	tracheostomy	NCIT:C50458	Tracheostomy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tracheostomy"", ""term"": {""id"": ""NCIT:C50458"", ""label"": ""Tracheostomy""}}}"
394	4058	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	broad spectrum antibiotic	NCIT:C2883	Broad Spectrum Antibiotic		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}"
395	4061	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	drainage procedure	NCIT:C15286	Drainage Procedure		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""drainage procedure"", ""term"": {""id"": ""NCIT:C15286"", ""label"": ""Drainage Procedure""}}}"
396	4061	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	1	treatment_term.qualifiers[1]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	tooth extraction	NCIT:C5189	Tooth Extraction		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tooth extraction"", ""term"": {""id"": ""NCIT:C5189"", ""label"": ""Tooth Extraction""}}}"
397	4070	4513	190	Lung Carcinoma	Lung_Carcinoma.yaml	pathophysiology	1	VEGFA-Mediated Angiogenesis	VEGFA-driven angiogenesis contributes to lung cancer progression and promotes a proangiogenic signaling network.	biological_processes[0]	angiogenesis	GO:0001525	angiogenesis	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
398	4149	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	biological_processes[0]	mismatch repair	GO:0006298	mismatch repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
399	4150	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	biological_processes[1]	DNA-templated DNA replication maintenance of fidelity	GO:0045005	DNA-templated DNA replication maintenance of fidelity	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
400	4151	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	biological_processes[2]	DNA damage response	GO:0006974	DNA damage response	modifier	0	biological_processes[2].modifier	modifier						ABNORMAL	"""ABNORMAL"""
401	4156	4598	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	1	Microsatellite Instability	Defective mismatch repair causes variations in the length of repetitive DNA sequences called microsatellites.	biological_processes[0]	DNA-templated DNA replication maintenance of fidelity	GO:0045005	DNA-templated DNA replication maintenance of fidelity	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
402	4161	4599	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	2	Accelerated Tumor Development	The accumulation of mutations in key genes leads to an increased risk of developing certain cancers at an earlier age.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
403	4165	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	biological_processes[0]	antigen processing and presentation of peptide antigen via MHC class I	GO:0002474	antigen processing and presentation of peptide antigen via MHC class I	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
404	4166	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	biological_processes[1]	type I interferon-mediated signaling pathway	GO:0060337	type I interferon-mediated signaling pathway	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
405	4167	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	biological_processes[2]	T cell mediated cytotoxicity directed against tumor cell target	GO:0002419	T cell mediated cytotoxicity directed against tumor cell target	modifier	0	biological_processes[2].modifier	modifier						INCREASED	"""INCREASED"""
406	4168	4601	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	4	Immune Checkpoint Blockade Sensitivity	Lynch-associated dMMR/MSI tumors with high neoantigen burden are enriched for anti-tumor T-cell activity and show strong responses to PD-1 blockade.	biological_processes[0]	T cell mediated cytotoxicity directed against tumor cell target	GO:0002419	T cell mediated cytotoxicity directed against tumor cell target	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
407	4176	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			acetylsalicylic acid	CHEBI:15365	acetylsalicylic acid		"{""preferred_term"": ""acetylsalicylic acid"", ""term"": {""id"": ""CHEBI:15365"", ""label"": ""acetylsalicylic acid""}}"
408	4194	4633	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	0	MET Exon 14 Splice Mutations	MET exon 14 skipping results from splice site mutations that cause exclusion of exon 14 during pre-mRNA splicing. Exon 14 encodes a juxtamembrane regulatory domain containing a CBL E3 ubiquitin ligase binding site (Y1003). Loss of this domain prevents receptor ubiquitination and degradation, leading to prolonged MET signaling after ligand stimulation.	biological_processes[0]	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
409	4195	4634	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	1	Prolonged MET Signaling	METex14 skipping results in prolonged receptor activation and downstream signaling through RAS-MAPK, PI3K-AKT, and STAT3 pathways. HGF (hepatocyte growth factor) ligand binding triggers signaling, but receptor downregulation is impaired.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
410	4196	4634	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	1	Prolonged MET Signaling	METex14 skipping results in prolonged receptor activation and downstream signaling through RAS-MAPK, PI3K-AKT, and STAT3 pathways. HGF (hepatocyte growth factor) ligand binding triggers signaling, but receptor downregulation is impaired.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
411	4197	4635	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	2	Cell Proliferation and Migration	MET signaling promotes cell proliferation, survival, motility, and invasion. The HGF-MET axis is particularly important for epithelial-mesenchymal transition and metastasis.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
412	4198	4636	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	3	MET Inhibitor Resistance	Resistance to MET inhibitors can develop through secondary MET kinase mutations (D1228N/V, Y1230C/H), MET amplification increase, or bypass pathway activation (KRAS, EGFR, HER3). On-target resistance mutations affect drug binding.	biological_processes[0]	response to drug	GO:0042493	response to drug	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
413	4210	4657	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Loss of MMR protein function (MLH1, MSH2, MSH6, or PMS2) impairs the recognition and repair of DNA replication errors. The MMR system normally corrects base-base mismatches and insertion/deletion loops at microsatellite sequences. Deficiency leads to accumulation of thousands of somatic mutations.	biological_processes[0]	mismatch repair	GO:0006298	mismatch repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
414	4212	4660	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	3	Frameshift Mutations in Tumor Suppressors	Coding microsatellites in tumor suppressor genes (TGFbetaRII, BAX, ACVR2, IGF2R) accumulate frameshift mutations, inactivating their tumor suppressive functions. TGFbetaRII frameshift is particularly common, disrupting TGF-beta growth inhibition.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
415	4214	4661	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	4	Neoantigen-Driven Immune Response	The high neoantigen burden in MSI-H tumors stimulates robust anti-tumor immunity. Tumor-infiltrating lymphocytes, particularly CD8+ cytotoxic T cells, recognize and attack tumor cells presenting neoantigens. However, tumors upregulate PD-L1 as an adaptive resistance mechanism.	biological_processes[0]	T cell mediated cytotoxicity	GO:0001913	T cell mediated cytotoxicity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
416	4226	4681	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	pathophysiology	0	Mismatch Repair Deficiency	Loss of functional mismatch repair (MMR) proteins impairs the ability to correct base-base mismatches and insertion-deletion loops during DNA replication. This leads to accumulation of mutations, particularly at microsatellite regions.	biological_processes[0]	mismatch repair	GO:0006298	mismatch repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
417	4228	4682	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	pathophysiology	1	Microsatellite Instability	Deficient mismatch repair leads to instability at microsatellite loci, short tandem repeat sequences throughout the genome. MSI-H status is defined by instability at multiple markers and serves as a biomarker for dMMR.	biological_processes[0]	DNA repair	GO:0006281	DNA repair	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
418	4229	4683	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	pathophysiology	2	Hypermutation and Neoantigen Generation	MMR deficiency causes a hypermutated tumor phenotype with high tumor mutational burden (TMB). Frameshift mutations at coding microsatellites generate neoantigens recognized by the immune system, explaining the high response rates to immune checkpoint inhibition.	biological_processes[0]	immune response	GO:0006955	immune response	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
419	4233	4687	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	0	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"
420	4259	4736	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	0	Asbestos-Induced Mesothelial Injury	Asbestos fibers penetrate the mesothelium and induce a cycle of cell death and regeneration. The fibers generate reactive oxygen species (ROS) and reactive nitrogen species that damage DNA, proteins, and lipids. Chronic inflammation driven by frustrated phagocytosis of long fibers promotes ongoing tissue damage and malignant transformation.	biological_processes[0]	inflammatory response	GO:0006954	inflammatory response	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
421	4260	4736	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	0	Asbestos-Induced Mesothelial Injury	Asbestos fibers penetrate the mesothelium and induce a cycle of cell death and regeneration. The fibers generate reactive oxygen species (ROS) and reactive nitrogen species that damage DNA, proteins, and lipids. Chronic inflammation driven by frustrated phagocytosis of long fibers promotes ongoing tissue damage and malignant transformation.	biological_processes[1]	response to oxidative stress	GO:0006979	response to oxidative stress	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
422	4263	4737	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	1	BAP1 Tumor Suppressor Inactivation	BAP1 (BRCA1-associated protein 1) is a nuclear deubiquitinase that regulates chromatin remodeling, DNA damage response, and cell cycle progression. BAP1 loss, through germline mutation or somatic inactivation, occurs in 60-70% of mesotheliomas and predisposes to malignant transformation. BAP1 loss impairs homologous recombination repair and chromatin regulation.	biological_processes[0]	histone deubiquitination	GO:0016578	histone deubiquitination	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
423	4264	4737	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	1	BAP1 Tumor Suppressor Inactivation	BAP1 (BRCA1-associated protein 1) is a nuclear deubiquitinase that regulates chromatin remodeling, DNA damage response, and cell cycle progression. BAP1 loss, through germline mutation or somatic inactivation, occurs in 60-70% of mesotheliomas and predisposes to malignant transformation. BAP1 loss impairs homologous recombination repair and chromatin regulation.	biological_processes[1]	DNA damage response	GO:0006974	DNA damage response	modifier	0	biological_processes[1].modifier	modifier						DECREASED	"""DECREASED"""
424	4266	4738	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	2	NF2/Merlin Inactivation	The NF2 gene encoding merlin is frequently inactivated in mesothelioma (approximately 50% of cases). Merlin loss activates YAP/TAZ signaling through the Hippo pathway, promoting cell proliferation and inhibiting contact-dependent growth arrest.	biological_processes[0]	Hippo signaling	GO:0035329	hippo signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
425	4268	4739	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	3	CDKN2A/p16 Loss	Homozygous deletion of CDKN2A, encoding p16INK4a and p14ARF, occurs in approximately 70% of mesotheliomas. Loss of p16 removes CDK4/6 inhibition, promoting cell cycle progression, while p14ARF loss compromises p53 stabilization.	biological_processes[0]	negative regulation of G1/S transition	GO:0045786	negative regulation of G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
426	4274	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
427	4274	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			pemetrexed	CHEBI:63616	pemetrexed		"{""preferred_term"": ""pemetrexed"", ""term"": {""id"": ""CHEBI:63616"", ""label"": ""pemetrexed""}}"
428	4285	4760	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	0	CCND1 Translocation and Cyclin D1 Overexpression	The t(11;14)(q13;q32) translocation places the CCND1 gene under control of the immunoglobulin heavy chain enhancer, causing constitutive overexpression of cyclin D1. This is the hallmark genetic event in MCL, occurring in virtually all cases, and drives cell cycle progression.	biological_processes[0]	G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
429	4286	4761	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	1	Cell Cycle Dysregulation	Cyclin D1 overexpression accelerates G1 to S phase transition by activating CDK4/6, which phosphorylates retinoblastoma protein (RB1) and releases E2F transcription factors. This overcomes normal cell cycle checkpoints and drives proliferation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
430	4287	4762	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	2	BTK and BCR Signaling Dependence	MCL cells are dependent on B-cell receptor signaling through BTK for survival. This pathway provides proliferative and anti-apoptotic signals essential for MCL cell maintenance. BTK inhibitors exploit this dependence, particularly effective in relapsed MCL.	biological_processes[0]	B cell activation	GO:0042113	B cell activation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
431	4288	4763	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	3	NF-kB Activation	Constitutive NF-kB signaling is common in MCL, driven by BCR signaling and genetic alterations affecting the NF-kB pathway. NF-kB promotes expression of anti-apoptotic genes contributing to MCL cell survival.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
432	4299	4772	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	0	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ibrutinib	CHEBI:76612	ibrutinib		"{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}"
433	4301	4773	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			acalabrutinib	CHEBI:167707	acalabrutinib		"{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}"
434	4306	4777	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	5	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"
435	4426	4905	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	2	Basal body localization without proper ciliogenesis	Basal bodies localize apically, yet cilia fail to form in many tissues.	biological_processes[0]	cilium assembly	GO:0060271	cilium assembly	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
436	4430	4906	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	3	Defective cilia formation across multiple tissues	Primary cilia fail to form in many tissues in vivo.	biological_processes[0]	cilium assembly	GO:0060271	cilium assembly	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
437	4434	4907	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	4	Loss of primary cilia (failed ciliogenesis)	Primary cilia are absent, reflecting failed ciliogenesis.	biological_processes[0]	cilium assembly	GO:0060271	cilium assembly	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
438	4439	4909	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	6	Impaired initiation of ciliogenesis	B9 proteins facilitate early ciliogenesis; disruption impairs initiation.	biological_processes[0]	cilium assembly	GO:0060271	cilium assembly	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
439	4440	4910	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	7	TMEM67 cleavage uncouples ciliogenesis and Wnt signaling	Proteolytic cleavage of TMEM67 separates ciliary assembly from Wnt pathway activity.	biological_processes[0]	cilium assembly	GO:0060271	cilium assembly	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
440	4441	4910	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	7	TMEM67 cleavage uncouples ciliogenesis and Wnt signaling	Proteolytic cleavage of TMEM67 separates ciliary assembly from Wnt pathway activity.	biological_processes[1]	Wnt signaling pathway	GO:0016055	Wnt signaling pathway	modifier	0	biological_processes[1].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
441	4442	4911	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	8	TMEM17 loss disrupts Sonic Hedgehog signaling	TMEM17 dysfunction at the ciliary transition zone abrogates Sonic Hedgehog signaling.	biological_processes[0]	hedgehog signaling pathway	GO:0007224	hedgehog signaling pathway	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
442	4445	4912	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	9	Altered Hedgehog signaling in neural tube patterning	Hedgehog signaling is altered during neural tube development.	biological_processes[0]	hedgehog signaling pathway	GO:0007224	hedgehog signaling pathway	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
443	4447	4913	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	10	Altered Hedgehog signaling in limb patterning	Hedgehog signaling is altered during limb development.	biological_processes[0]	hedgehog signaling pathway	GO:0007224	hedgehog signaling pathway	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
444	4453	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	treatment_term	surgical repair	MAXO:0009072	surgical repair	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	excision	NCIT:C15232	Excision		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}"
445	4456	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	treatment_term	surgical repair	MAXO:0009072	surgical repair	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	shunt device	NCIT:C50174	Shunt Device		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""shunt device"", ""term"": {""id"": ""NCIT:C50174"", ""label"": ""Shunt Device""}}}"
446	4459	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	treatment_term	surgical repair	MAXO:0009072	surgical repair	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	excision	NCIT:C15232	Excision		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}"
447	4462	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	treatment_term	gene therapy	MAXO:0001001	gene therapy	qualifier	0	treatment_term.qualifiers[0]	has participant	RO:0000057	has participant	CC2D2A	hgnc:29253	CC2D2A		"{""predicate"": {""preferred_term"": ""has participant"", ""term"": {""id"": ""RO:0000057"", ""label"": ""has participant""}}, ""value"": {""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}}"
448	4469	4931	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	0	RET Proto-Oncogene Activation	Activating mutations in the RET receptor tyrosine kinase lead to constitutive kinase activity without ligand binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting C-cell proliferation and survival.	biological_processes[0]	receptor signaling protein tyrosine kinase activity	GO:0004716	receptor signaling protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
449	4472	4932	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	1	RAS-MAPK Pathway Activation	RET activation stimulates the RAS-RAF-MEK-ERK signaling cascade, driving uncontrolled C-cell proliferation. This pathway is a major effector of RET-mediated transformation in MTC.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
450	4473	4933	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	RET activation recruits PI3K and activates the PI3K-AKT-mTOR signaling cascade, promoting C-cell survival and resistance to apoptosis. This cooperates with MAPK signaling to drive MTC tumorigenesis.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
451	4480	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vandetanib	CHEBI:49960	vandetanib		"{""preferred_term"": ""vandetanib"", ""term"": {""id"": ""CHEBI:49960"", ""label"": ""vandetanib""}}"
452	4480	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			cabozantinib	CHEBI:72317	cabozantinib		"{""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}"
453	4485	4951	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	0	SHH Pathway Activation	The SHH pathway is activated through loss of function mutations in PTCH1 (receptor that normally inhibits SMO), activating mutations in SMO, loss of SUFU (negative regulator), or amplification of downstream effectors (GLI2, MYCN). This leads to constitutive activation of GLI transcription factors.	biological_processes[0]	smoothened signaling pathway	GO:0007224	smoothened signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
454	4487	4952	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	1	GLI Transcription Factor Activation	Activated SMO leads to nuclear translocation of GLI transcription factors (GLI1, GLI2) which activate target genes including PTCH1 (feedback), GLI1, MYCN, CCND1, and BCL2. GLI2 amplification can drive pathway activation independently of upstream components.	biological_processes[0]	positive regulation of gene expression	GO:0010628	positive regulation of gene expression	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
455	4489	4953	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	2	Cerebellar Granule Cell Proliferation	SHH signaling normally controls proliferation of granule neuron precursors in the external granule layer during cerebellar development. Constitutive pathway activation leads to unchecked proliferation of these precursors, resulting in tumor formation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
456	4490	4953	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	2	Cerebellar Granule Cell Proliferation	SHH signaling normally controls proliferation of granule neuron precursors in the external granule layer during cerebellar development. Constitutive pathway activation leads to unchecked proliferation of these precursors, resulting in tumor formation.	biological_processes[1]	cerebellum development	GO:0021549	cerebellum development	modifier	0	biological_processes[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
457	4501	4971	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	0	WNT/Beta-Catenin Pathway Activation	Activating mutations in CTNNB1 (beta-catenin) prevent phosphorylation at serine/threonine residues in exon 3, blocking proteasomal degradation. This leads to nuclear accumulation of beta-catenin, which complexes with TCF/LEF transcription factors to activate WNT target genes.	biological_processes[0]	Wnt signaling pathway	GO:0016055	Wnt signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
458	4503	4972	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	1	Nuclear Beta-Catenin Accumulation	Stabilized beta-catenin accumulates in the nucleus where it acts as a transcriptional coactivator with TCF/LEF family transcription factors. Nuclear beta-catenin immunostaining is a diagnostic hallmark of WNT-activated medulloblastoma.	biological_processes[0]	canonical Wnt signaling pathway	GO:0060070	canonical Wnt signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
459	4504	4973	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	2	WNT Target Gene Activation	Nuclear beta-catenin/TCF complexes drive expression of WNT target genes including MYC, CCND1 (cyclin D1), AXIN2, and DKK1. These genes promote proliferation and can serve as biomarkers of WNT pathway activation.	biological_processes[0]	positive regulation of gene expression	GO:0010628	positive regulation of gene expression	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
460	4506	4974	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	3	Cell Proliferation and Tumor Formation	WNT pathway activation drives proliferation of cerebellar progenitor cells, likely from the lower rhombic lip region. Despite constitutive pathway activation, these tumors have favorable biology, possibly due to their differentiation state or immunological features.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
461	4558	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	treatment_term	corticosteroid injection	MAXO:0000640	corticosteroid agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	triamcinolone	NCIT:C901	Triamcinolone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}"
462	4562	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF-α antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF-α-driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	infliximab	NCIT:C1789	Infliximab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}"
463	4565	5039	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	3	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent class	NCIT:C20401	Monoclonal Antibody					"{""predicate"": {""preferred_term"": ""therapeutic agent class"", ""term"": {""id"": ""NCIT:C20401"", ""label"": ""Monoclonal Antibody""}}}"
464	4589	5065	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	0	Viral T Antigen Oncogenesis	In MCPyV-positive MCC, clonally integrated virus expresses truncated large T antigen (LT) that binds and inactivates RB tumor suppressor protein, releasing E2F transcription factors and driving cell cycle progression. Small T antigen (sT) promotes proliferation through multiple mechanisms including 4E-BP1 hyperphosphorylation and cap-dependent translation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
465	4591	5066	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	1	RB1 Pathway Inactivation	In virus-positive MCC, viral large T antigen binds and inactivates RB1 protein. In virus-negative MCC, RB1 is frequently inactivated by somatic mutations. In both cases, loss of RB1 function releases E2F transcription factors to drive cell cycle progression and proliferation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
466	4593	5067	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	2	UV-Induced Mutagenesis	In virus-negative MCC (approximately 20%), high levels of UV-induced mutations (C>T transitions at dipyrimidine sites) drive oncogenesis. These tumors have among the highest tumor mutational burdens of any cancer and frequently harbor mutations in TP53, RB1, and other tumor suppressors.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
467	4596	5068	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	3	Uncontrolled Merkel Cell Proliferation	Whether driven by viral T antigens or UV-induced mutations, MCC cells exhibit uncontrolled proliferation. The neuroendocrine differentiation is retained, with expression of characteristic markers including CK20, chromogranin, and synaptophysin.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
468	4694	5199	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	0	RET Oncogene Activation	Germline activating mutations in RET cause ligand-independent receptor dimerization and constitutive tyrosine kinase activation. Unlike tumor suppressor syndromes, only one mutant allele is required (no second hit). This represents a gain-of-function oncogene mechanism.	biological_processes[0]	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
469	4696	5200	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	1	Downstream Signaling Cascade Activation	Constitutively active RET phosphorylates intracellular substrates and activates RAS-MAPK, PI3K-AKT, and JAK-STAT signaling pathways. These promote cell proliferation, survival, and transformation of neuroendocrine cell populations.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
470	4697	5200	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	1	Downstream Signaling Cascade Activation	Constitutively active RET phosphorylates intracellular substrates and activates RAS-MAPK, PI3K-AKT, and JAK-STAT signaling pathways. These promote cell proliferation, survival, and transformation of neuroendocrine cell populations.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
471	4700	5201	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	2	Neuroendocrine Cell Transformation	Constitutive RET signaling drives transformation of neuroendocrine cell populations. C-cell hyperplasia precedes MTC development and serves as a preneoplastic lesion. Similar processes affect adrenal chromaffin cells leading to pheochromocytoma.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
472	4708	5210	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	1	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			selpercatinib	CHEBI:175074	selpercatinib		"{""preferred_term"": ""selpercatinib"", ""term"": {""id"": ""CHEBI:175074"", ""label"": ""selpercatinib""}}"
473	4856	5362	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	1	ARF-p53 Pathway Disruption	Wild-type NPM1 stabilizes the ARF tumor suppressor in the nucleolus. Cytoplasmic NPM1 delocalizes ARF, reducing its ability to inhibit MDM2 and stabilize p53. This impairs the p53-mediated response to oncogenic stress and DNA damage.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
474	4858	5363	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	2	HOX Gene Dysregulation	NPM1-mutated AML consistently shows upregulation of HOXA and HOXB cluster genes, including HOXA9 and MEIS1. These transcription factors promote self-renewal of leukemic cells and block normal myeloid differentiation. This HOX signature is a defining feature of NPM1-mutated AML.	biological_processes[0]	myeloid cell differentiation	GO:0030099	myeloid cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
475	4859	5364	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	3	Impaired Tumor Suppression	The combined effects of ARF-p53 pathway disruption and loss of NPM1 nucleolar functions impair the cell's ability to respond to oncogenic signals with appropriate growth arrest or apoptosis.	biological_processes[0]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
476	4868	5372	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	1	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"
477	4874	5379	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	0	NRAS Q61 Oncogenic Mutation	NRAS mutations at codon 61 (Q61R, Q61K, Q61L) impair intrinsic GTPase activity and reduce sensitivity to GTPase-activating proteins (GAPs), resulting in constitutively GTP-bound active NRAS. This locks the protein in its active conformation, continuously stimulating downstream effector pathways.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
478	4875	5380	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	1	Dual MAPK and PI3K Pathway Activation	Unlike BRAF mutations that primarily activate MAPK signaling, oncogenic NRAS simultaneously activates both the RAF-MEK-ERK (MAPK) pathway and the PI3K-AKT pathway. This dual pathway activation contributes to the aggressive biology and relative treatment resistance of NRAS-mutant melanoma.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
479	4878	5381	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	2	Uncontrolled Melanocyte Proliferation	Constitutive MAPK pathway activation downstream of mutant NRAS drives melanocyte proliferation through ERK-mediated transcriptional programs promoting cell cycle entry and progression.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
480	4879	5382	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	3	Enhanced Cell Survival	PI3K-AKT pathway activation downstream of NRAS promotes melanoma cell survival through phosphorylation and inactivation of pro-apoptotic proteins, activation of mTOR signaling, and metabolic reprogramming. This contributes to therapy resistance and the need for combination treatment strategies.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
481	4886	5396	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	pathophysiology	0	NTRK Gene Fusion and Constitutive TRK Activation	Chromosomal rearrangements fuse the kinase domain of NTRK genes with various upstream partners that provide dimerization domains. This creates constitutively active chimeric TRK proteins that signal independently of neurotrophin ligands.	biological_processes[0]	protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
482	4887	5397	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	pathophysiology	1	RAS-MAPK Pathway Activation	Constitutive TRK activation drives the RAS-RAF-MEK-ERK signaling cascade, promoting uncontrolled cell proliferation. This is a major effector pathway of TRK-mediated oncogenesis.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
483	4888	5398	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	TRK activation recruits PI3K and stimulates AKT-mTOR signaling, promoting cell survival and resistance to apoptosis. Combined with MAPK activation, this drives aggressive tumor growth.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
484	4892	5402	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	1	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			entrectinib	CHEBI:195558	entrectinib		"{""preferred_term"": ""entrectinib"", ""term"": {""id"": ""CHEBI:195558"", ""label"": ""entrectinib""}}"
485	4913	5437	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	0	EBV Latent Membrane Protein 1 (LMP1) Signaling	LMP1 is the primary EBV oncoprotein in NPC, functioning as a constitutively active receptor that mimics CD40 signaling. LMP1 activates NF-kB, MAPK, and PI3K/AKT pathways, promoting cell survival, proliferation, and epithelial-mesenchymal transition.	biological_processes[0]	NF-kappaB signaling	GO:0038061	NIK/NF-kappaB signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
486	4914	5437	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	0	EBV Latent Membrane Protein 1 (LMP1) Signaling	LMP1 is the primary EBV oncoprotein in NPC, functioning as a constitutively active receptor that mimics CD40 signaling. LMP1 activates NF-kB, MAPK, and PI3K/AKT pathways, promoting cell survival, proliferation, and epithelial-mesenchymal transition.	biological_processes[1]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
487	4916	5438	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	1	LMP2A-Mediated B Cell Receptor Mimicry	LMP2A is a viral protein that mimics an activated B cell receptor, providing survival signals that prevent viral lytic reactivation and maintain latency. In epithelial cells, LMP2A activates PI3K/AKT and promotes cell motility.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
488	4919	5441	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	4	Immune Evasion	EBV-infected NPC cells evade immune surveillance through multiple mechanisms including PD-L1 upregulation, suppression of antigen presentation, and recruitment of regulatory T cells. This provides rationale for immune checkpoint inhibition.	biological_processes[0]	negative regulation of T cell mediated immunity	GO:0002710	negative regulation of T cell mediated immunity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
489	4927	5449	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	1	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
490	4929	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			gemcitabine	CHEBI:175901	gemcitabine		"{""preferred_term"": ""gemcitabine"", ""term"": {""id"": ""CHEBI:175901"", ""label"": ""gemcitabine""}}"
491	4929	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
492	4970	5501	230	Neuroblastoma	Neuroblastoma.yaml	pathophysiology	0	Neural Crest Developmental Arrest	Neuroblastoma arises from neural crest-derived sympathoadrenal progenitor cells that fail to complete differentiation. The tumor cells retain characteristics of immature neuroblasts with variable capacity for sympathetic neuronal differentiation.	biological_processes[0]	cell differentiation	GO:0030154	cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
493	4972	5502	230	Neuroblastoma	Neuroblastoma.yaml	pathophysiology	1	MYCN-Driven Proliferation	MYCN amplification results in massive overexpression of the MYCN transcription factor, which drives cell cycle progression, inhibits differentiation, and promotes genomic instability. MYCN-amplified tumors have a distinct aggressive phenotype with rapid growth and early metastasis.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
494	4973	5503	230	Neuroblastoma	Neuroblastoma.yaml	pathophysiology	2	ALK Signaling Activation	ALK (anaplastic lymphoma kinase) is activated by point mutations in approximately 8-10% of neuroblastomas, and by amplification in additional cases. ALK mutations are enriched in familial neuroblastoma and represent a therapeutic target for ALK inhibitors.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
495	4981	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
496	4981	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"
497	4981	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
498	4990	5519	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	0	NF1 Tumor Suppressor Loss	Germline heterozygous NF1 mutations result in haploinsufficiency for neurofibromin function. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates neurofibromin completely, resulting in loss of RAS negative regulation and driving tumorigenesis. This follows Knudson's two-hit hypothesis.	biological_processes[0]	regulation of Ras protein signal transduction	GO:0046578	regulation of Ras protein signal transduction	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
499	4991	5520	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	1	RAS-MAPK Pathway Hyperactivation	Neurofibromin normally accelerates GTP hydrolysis on RAS proteins, promoting the inactive GDP-bound state. Loss of neurofibromin results in prolonged RAS-GTP accumulation and constitutive activation of the RAS-RAF-MEK-ERK cascade, driving cell proliferation and survival.	biological_processes[0]	Ras protein signal transduction	GO:0007265	Ras protein signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
500	4992	5520	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	1	RAS-MAPK Pathway Hyperactivation	Neurofibromin normally accelerates GTP hydrolysis on RAS proteins, promoting the inactive GDP-bound state. Loss of neurofibromin results in prolonged RAS-GTP accumulation and constitutive activation of the RAS-RAF-MEK-ERK cascade, driving cell proliferation and survival.	biological_processes[1]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
501	4994	5521	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	2	Uncontrolled Neural Crest Cell Proliferation	Neural crest-derived cells (Schwann cells, melanocytes) show particular dependence on RAS-MAPK signaling. Loss of neurofibromin drives uncontrolled proliferation of these cell types, resulting in neurofibromas (Schwann cell tumors) and hyperpigmented skin lesions (cafe-au-lait macules from melanocyte hyperproliferation).	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
502	5030	5536	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	pathophysiology	0	AQP4-IgG-Mediated Astrocyte Injury	Autoantibodies against AQP4 bind astrocytic end-feet and trigger complement-dependent astrocyte damage, driving neuroinflammation.	biological_processes[0]	complement activation	GO:0006956	complement activation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
503	5031	5537	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	pathophysiology	1	AQP4 Endocytosis and Complement-Independent Cytotoxicity	NMO-IgG can induce complement-independent astrocyte injury, with antibody- induced endocytosis of AQP4 implicated in this mechanism.	biological_processes[0]	endocytosis	GO:0006897	endocytosis	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
504	5305	5848	248	Osteosarcoma	Osteosarcoma.yaml	pathophysiology	1	Tumor Immune Microenvironment Remodeling	Osteosarcoma progression involves interactions with immune cells in the tumor microenvironment, including tumor-infiltrating lymphocytes and tumor-associated macrophages, alongside immune checkpoint expression.	biological_processes[0]	immune response	GO:0006955	immune response	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
505	5312	5857	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	0	PIK3CA Oncogenic Mutations	Activating PIK3CA mutations occur as somatic events in breast cancer cells. Hotspot mutations cluster in the helical domain (E542K, E545K) and kinase domain (H1047R). These mutations cause constitutive PI3K activity independent of upstream receptor tyrosine kinase signaling.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
506	5313	5858	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	1	Constitutive PI3K-AKT Pathway Activation	Mutant PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruiting and activating AKT (protein kinase B). Activated AKT phosphorylates numerous substrates promoting cell survival, proliferation, metabolism, and resistance to apoptosis.	biological_processes[0]	phosphatidylinositol-mediated signaling	GO:0048015	phosphatidylinositol-mediated signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
507	5314	5858	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	1	Constitutive PI3K-AKT Pathway Activation	Mutant PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruiting and activating AKT (protein kinase B). Activated AKT phosphorylates numerous substrates promoting cell survival, proliferation, metabolism, and resistance to apoptosis.	biological_processes[1]	protein kinase B signaling	GO:0043491	protein kinase B signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
508	5315	5859	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	2	mTOR Pathway Activation	AKT activates mTORC1 by inhibiting the TSC1/TSC2 complex, relieving suppression of the small GTPase Rheb. Active mTORC1 promotes protein synthesis, cell growth, and metabolic reprogramming through S6K1 and 4E-BP1 phosphorylation.	biological_processes[0]	TOR signaling	GO:0031929	TOR signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
509	5316	5860	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	3	Cell Survival and Proliferation	PI3K-AKT signaling promotes cell survival through phosphorylation and inactivation of pro-apoptotic proteins (BAD, FOXO transcription factors) and cell proliferation through multiple mechanisms including cyclin D1 stabilization.	biological_processes[0]	negative regulation of apoptotic process	GO:0043066	negative regulation of apoptotic process	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
510	5317	5860	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	3	Cell Survival and Proliferation	PI3K-AKT signaling promotes cell survival through phosphorylation and inactivation of pro-apoptotic proteins (BAD, FOXO transcription factors) and cell proliferation through multiple mechanisms including cyclin D1 stabilization.	biological_processes[1]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
511	5318	5861	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	4	Endocrine Resistance	In ER+ breast cancer, PIK3CA mutations confer partial resistance to endocrine therapy through crosstalk between PI3K and ER signaling. PI3K pathway activation can maintain tumor growth despite estrogen deprivation.	biological_processes[0]	intracellular estrogen receptor signaling pathway	GO:0030520	intracellular estrogen receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
512	5412	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	triamcinolone	NCIT:C901	Triamcinolone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}"
513	5412	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	prednisone	NCIT:C770	Prednisone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""prednisone"", ""term"": {""id"": ""NCIT:C770"", ""label"": ""Prednisone""}}}"
514	5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	methotrexate	NCIT:C642	Methotrexate		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""methotrexate"", ""term"": {""id"": ""NCIT:C642"", ""label"": ""Methotrexate""}}}"
515	5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	mycophenolate mofetil	NCIT:C1468	Mycophenolate Mofetil		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""NCIT:C1468"", ""label"": ""Mycophenolate Mofetil""}}}"
516	5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	2	treatment_term.qualifiers[2]	therapeutic agent	NCIT:C2259	Therapeutic Agent	azathioprine	NCIT:C290	Azathioprine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}"
517	5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	3	treatment_term.qualifiers[3]	therapeutic agent	NCIT:C2259	Therapeutic Agent	cyclosporine	NCIT:C406	Cyclosporine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""cyclosporine"", ""term"": {""id"": ""NCIT:C406"", ""label"": ""Cyclosporine""}}}"
518	5426	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	adalimumab	NCIT:C65216	Adalimumab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adalimumab"", ""term"": {""id"": ""NCIT:C65216"", ""label"": ""Adalimumab""}}}"
519	5426	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	infliximab	NCIT:C1789	Infliximab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}"
520	5533	6065	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	1	mTORC1 pathway hyperactivation	"LKB1-deficient tissues and hamartomas show increased mTORC1 signaling that promotes polyp growth and proliferation.
"	biological_processes[0]	mTORC1 signaling	GO:0031929	TOR signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
521	5563	6093	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	0	BCR-ABL1 Fusion Oncogene in Lymphoid Progenitors	The t(9;22)(q34;q11) translocation fuses BCR on chromosome 22 with ABL1 on chromosome 9, creating the Philadelphia chromosome. In ALL, the fusion typically produces the p190 BCR-ABL1 protein (compared to p210 in CML), which has enhanced transforming activity in lymphoid cells. The fusion kinase is constitutively active, driving proliferation and survival signaling.	biological_processes[0]	protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
522	5564	6094	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	1	Constitutive Signaling Pathway Activation	BCR-ABL1 activates RAS-MAPK, PI3K-AKT, and JAK-STAT signaling pathways independently of normal growth factor regulation. This drives uncontrolled proliferation and confers resistance to apoptosis, enabling leukemic transformation of B-lymphoid progenitors.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
523	5566	6095	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	2	B-lymphoid Differentiation Block	BCR-ABL1 signaling interferes with normal B-cell development, arresting cells at an immature lymphoblast stage. The resulting cells express B-lineage markers (CD19, CD22) but lack complete B-cell maturation. IKZF1 (Ikaros) deletions, common in Ph+ ALL, further impair B-cell development.	biological_processes[0]	B cell differentiation	GO:0030183	B cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
524	5567	6096	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	3	Apoptosis Resistance	BCR-ABL1 activates PI3K-AKT signaling, phosphorylating and inactivating pro-apoptotic proteins including BAD. This confers resistance to normal apoptotic signals and contributes to the aggressive clinical behavior of Ph+ ALL.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
525	5576	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			dasatinib	CHEBI:49375	dasatinib		"{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}"
526	5576	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
527	5579	6105	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	1	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ponatinib	CHEBI:78543	ponatinib		"{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}"
528	5584	6113	259	Phenylketonuria	Phenylketonuria.yaml	computational_models	0	Multi-compartment PKU FBA Model	Three-compartment FBA model with explicit blood-brain barrier transport for aromatic amino acids	perturbations[0]	PAH	hgnc:8582	PAH	modifier	0	perturbations[0].modifier	modifier						ABSENT	"""ABSENT"""
529	5585	6114	259	Phenylketonuria	Phenylketonuria.yaml	computational_models	1	Recon3D with PAH knockout	Human genome-scale metabolic model simulating phenylalanine hydroxylase deficiency	perturbations[0]	PAH	hgnc:8582	PAH	modifier	0	perturbations[0].modifier	modifier						ABSENT	"""ABSENT"""
530	5604	6148	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	0	Succinate Dehydrogenase Complex Dysfunction	Mutations in SDHx genes (SDHA, SDHB, SDHC, SDHD, SDHAF2) impair mitochondrial complex II function, leading to succinate accumulation. Succinate acts as an oncometabolite, inhibiting alpha-ketoglutarate-dependent dioxygenases and causing pseudohypoxia and epigenetic dysregulation.	biological_processes[0]	succinate dehydrogenase activity	GO:0000104	succinate dehydrogenase activity	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
531	5606	6149	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	1	Pseudohypoxia and HIF Activation	SDHx and VHL mutations cause constitutive stabilization of hypoxia-inducible factors (HIF1/2) under normoxic conditions. This pseudohypoxic state activates genes promoting angiogenesis, glycolysis, and cell survival, driving tumorigenesis.	biological_processes[0]	response to hypoxia	GO:0001666	response to hypoxia	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
532	5607	6150	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	2	RET Proto-Oncogene Activation	Germline RET mutations in MEN2 syndrome cause pheochromocytoma through constitutive receptor tyrosine kinase activation. RET-driven pheochromocytomas have distinct catecholamine profiles (epinephrine-predominant) compared to SDHx-related tumors.	biological_processes[0]	receptor signaling protein tyrosine kinase activity	GO:0004716	receptor signaling protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
533	5608	6151	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	3	Catecholamine Hypersecretion	Secreting PPGLs produce excess catecholamines (norepinephrine, epinephrine, dopamine), causing characteristic symptoms. The catecholamine profile provides clues to underlying genetics: norepinephrine-predominant suggests SDHx/VHL, epinephrine-predominant suggests RET/NF1.	biological_processes[0]	catecholamine biosynthetic process	GO:0042423	catecholamine biosynthetic process	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
534	5703	6269	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	0	JAK2 V617F Constitutive Activation	The JAK2 V617F mutation in the pseudokinase domain eliminates auto-inhibition, causing constitutive JAK2 tyrosine kinase activity. This renders erythroid progenitors hypersensitive to or independent of erythropoietin, driving uncontrolled red blood cell production.	biological_processes[0]	protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
535	5705	6270	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	1	STAT5 Hyperactivation	Constitutive JAK2 activation leads to sustained STAT5 phosphorylation and transcriptional activation of genes promoting erythroid proliferation and survival, including BCL-XL and cyclin D1.	biological_processes[0]	JAK-STAT signaling pathway	GO:0007259	JAK-STAT cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
536	5706	6271	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	2	Erythropoietin-Independent Erythropoiesis	JAK2 V617F-mutant erythroid progenitors can proliferate and differentiate in the absence of erythropoietin, forming endogenous erythroid colonies (EEC) in culture. This erythropoietin independence is a diagnostic hallmark of PV.	biological_processes[0]	erythrocyte differentiation	GO:0030218	erythrocyte differentiation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
537	5707	6272	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	3	Hyperviscosity and Thrombosis Risk	Elevated red blood cell mass increases blood viscosity and promotes thrombosis. The prothrombotic state is multifactorial, including abnormal red cell interactions, platelet activation, and endothelial dysfunction.	biological_processes[0]	blood coagulation	GO:0007596	blood coagulation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
538	5717	6282	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	2	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"
539	5719	6283	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	3	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ruxolitinib	CHEBI:66919	ruxolitinib		"{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}"
540	5809	6392	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL all converge on constitutive activation of JAK-STAT signaling. JAK2 V617F directly activates the kinase; CALR and MPL mutations lead to activation of MPL receptor signaling.	biological_processes[0]	JAK-STAT signaling pathway	GO:0007259	JAK-STAT cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
541	5811	6393	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	1	Abnormal Megakaryopoiesis	Driver mutations cause aberrant megakaryocyte proliferation and maturation. Megakaryocytes show characteristic atypia with clustering, abnormal lobation, and defective platelet production.	biological_processes[0]	megakaryocyte differentiation	GO:0030219	megakaryocyte differentiation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
542	5812	6394	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	2	Cytokine-Mediated Marrow Fibrosis	Atypical megakaryocytes release profibrotic cytokines including TGF-beta, PDGF, and bFGF, stimulating marrow stromal cells to deposit reticulin and collagen fibers. Progressive fibrosis replaces normal hematopoietic tissue.	biological_processes[0]	extracellular matrix organization	GO:0030198	extracellular matrix organization	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
543	5814	6395	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	3	Extramedullary Hematopoiesis	As bone marrow function declines due to fibrosis, hematopoiesis shifts to spleen, liver, and other sites. This causes massive splenomegaly and hepatomegaly with associated symptoms.	biological_processes[0]	hematopoiesis	GO:0030097	hemopoiesis	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
544	5821	6404	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	0	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ruxolitinib	CHEBI:66919	ruxolitinib		"{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}"
545	5825	6407	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	3	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"
546	5827	6408	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	4	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			anagrelide	CHEBI:142290	anagrelide		"{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}"
547	5894	6483	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	1	Elevated PI3K/AKT signaling in AKT1-mutant cells	"AKT1 p.E17K drives increased PI3K/AKT pathway activity in mutation-positive cells, promoting downstream overgrowth signals.
"	biological_processes[0]	phosphatidylinositol 3-kinase/protein kinase B signal transduction	GO:0043491	phosphatidylinositol 3-kinase/protein kinase B signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
548	5895	6484	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	2	Increased pAKT signaling in AKT1-mutant lesion cells	"Lesion cells harboring AKT1 p.E17K show increased pAKT signaling within hyperplastic regions.
"	biological_processes[0]	protein phosphorylation	GO:0006468	protein phosphorylation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
549	5896	6485	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	3	Non-cell-autonomous pAKT activation in adjacent cells	"AKT1-mutant clones can induce increased pAKT signaling in nearby mutation-negative cells, consistent with non-cell-autonomous lesion propagation.
"	biological_processes[0]	cell-cell signaling	GO:0007267	cell-cell signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
550	5898	6486	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	4	AKT overactivation induces excessive vasculogenesis	"AKT1 activation increases vascular connectivity and promotes vasculogenesis with enhanced vascular sprouting.
"	biological_processes[0]	vasculogenesis	GO:0001570	vasculogenesis	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
551	5899	6486	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	4	AKT overactivation induces excessive vasculogenesis	"AKT1 activation increases vascular connectivity and promotes vasculogenesis with enhanced vascular sprouting.
"	biological_processes[1]	angiogenesis	GO:0001525	angiogenesis	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
552	5901	6487	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	5	Mural cell dysfunction destabilizes vascular connections	"AKT-driven vascular malformations include dysfunctional PDGFRβ+ mural cells with impaired matrix secretion, contributing to unstable vessel connections.
"	biological_processes[0]	extracellular matrix organization	GO:0030198	extracellular matrix organization	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
553	5924	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	miransertib	NCIT:C99172	Miransertib		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""miransertib"", ""term"": {""id"": ""NCIT:C99172"", ""label"": ""Miransertib""}}}"
554	5942	6553	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	pathophysiology	1	Cytokine Pathway Activation	Dysregulated cytokine signaling, particularly IL-23/IL-17 and TNF pathways, sustains inflammatory responses in affected tissues.	biological_processes[0]	cytokine-mediated signaling pathway	GO:0019221	cytokine-mediated signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
555	5950	6562	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	diagnosis	1	Right Heart Catheterization		diagnosis_term	right heart catheterization	MAXO:0035118	cardiac catheterization	located_in	0	diagnosis_term.located_in	located_in			right cardiac chamber	UBERON:0035554	right cardiac chamber		"{""preferred_term"": ""right cardiac chamber"", ""term"": {""id"": ""UBERON:0035554"", ""label"": ""right cardiac chamber""}}"
556	5993	6604	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	pathophysiology	0	RET Fusion and Constitutive Kinase Activation	Chromosomal rearrangements fuse the RET tyrosine kinase domain with upstream partners that provide dimerization domains. This creates constitutively active chimeric proteins that signal independently of RET ligands (GDNF family members).	biological_processes[0]	receptor signaling protein tyrosine kinase activity	GO:0004716	receptor signaling protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
557	5995	6605	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	pathophysiology	1	RAS-MAPK Pathway Activation	Constitutive RET kinase activation drives the RAS-RAF-MEK-ERK signaling cascade, promoting uncontrolled thyroid follicular cell proliferation. This is a major effector of RET-mediated thyroid tumorigenesis.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
558	5996	6606	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	RET activation recruits PI3K and stimulates AKT-mTOR signaling, promoting cell survival and resistance to apoptosis. Combined with MAPK activation, this drives thyroid cancer progression.	biological_processes[0]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
559	6004	6614	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	4	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"
560	6008	6622	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	0	RET Gene Rearrangement	RET rearrangements result from chromosomal inversions or translocations that fuse the RET kinase domain (10q11.21) to an N-terminal partner gene. The partner gene provides a dimerization domain, causing constitutive RET kinase activation independent of ligand. RET normally signals through GDNF family ligands and GFR-alpha co-receptors.	biological_processes[0]	protein kinase activity	GO:0004672	protein kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
561	6009	6623	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive RET Signaling	RET fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and PLCgamma pathways. RET also activates SRC family kinases and JAK-STAT signaling.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
562	6010	6623	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive RET Signaling	RET fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and PLCgamma pathways. RET also activates SRC family kinases and JAK-STAT signaling.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
563	6011	6624	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	2	Oncogene Addiction	RET-rearranged tumors exhibit oncogene addiction, becoming dependent on continued RET signaling for survival. Selective RET inhibition leads to rapid and durable tumor responses.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
564	6012	6625	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	3	RET Inhibitor Resistance	Resistance to selective RET inhibitors can develop through secondary RET kinase mutations (G810R/S/C solvent front mutations, V804L/M gatekeeper), RET amplification, or bypass pathway activation (MET, KRAS, BRAF). Solvent front mutations are the most common resistance mechanism.	biological_processes[0]	response to drug	GO:0042493	response to drug	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
565	6024	6642	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	0	ROS1 Gene Rearrangement	ROS1 rearrangements result from chromosomal translocations that fuse the ROS1 kinase domain (6q22) to an N-terminal partner gene. The partner provides a dimerization domain, causing constitutive ROS1 kinase activation independent of ligand. ROS1 shares ~49% amino acid identity with ALK in the kinase domain, explaining cross-sensitivity to ALK inhibitors.	biological_processes[0]	protein kinase activity	GO:0004672	protein kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
566	6025	6643	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ROS1 Signaling	ROS1 fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration. ROS1 shares significant kinase domain homology with ALK.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
567	6026	6643	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ROS1 Signaling	ROS1 fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration. ROS1 shares significant kinase domain homology with ALK.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
568	6027	6643	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ROS1 Signaling	ROS1 fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration. ROS1 shares significant kinase domain homology with ALK.	biological_processes[2]	JAK-STAT cascade	GO:0007259	JAK-STAT cascade	modifier	0	biological_processes[2].modifier	modifier						INCREASED	"""INCREASED"""
569	6028	6644	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	2	Oncogene Addiction	ROS1-rearranged tumors exhibit oncogene addiction, becoming dependent on continued ROS1 signaling for survival. ROS1 inhibition leads to dramatic tumor responses, often within days to weeks of starting therapy.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
570	6029	6645	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	3	ROS1 Inhibitor Resistance	Resistance to ROS1 inhibitors develops through ROS1-dependent mechanisms (secondary mutations like G2032R, D2033N, L2026M) or ROS1-independent bypass pathways (MET amplification, KRAS mutations, EGFR activation). The G2032R solvent front mutation is the most common and confers resistance to crizotinib.	biological_processes[0]	response to drug	GO:0042493	response to drug	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
571	6070	6716	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	0	RB1 Tumor Suppressor Inactivation	The RB1 gene encodes the retinoblastoma protein (pRB), a critical regulator of the cell cycle. Biallelic RB1 loss removes the constraint on E2F transcription factors, allowing uncontrolled progression through the G1/S checkpoint. Retinoblastoma exemplifies Knudson's two-hit hypothesis: in hereditary cases, one mutation is inherited and the second is somatic; in sporadic cases, both mutations occur somatically in the same cell.	biological_processes[0]	G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
572	6072	6717	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	1	Loss of Cell Cycle Checkpoint Control	pRB normally binds and inhibits E2F transcription factors during G1 phase. When pRB is phosphorylated by cyclin-dependent kinases or functionally lost, E2F is released to activate genes required for S-phase entry, including cyclins, DNA replication factors, and proliferative genes.	biological_processes[0]	cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
573	6073	6717	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	1	Loss of Cell Cycle Checkpoint Control	pRB normally binds and inhibits E2F transcription factors during G1 phase. When pRB is phosphorylated by cyclin-dependent kinases or functionally lost, E2F is released to activate genes required for S-phase entry, including cyclins, DNA replication factors, and proliferative genes.	biological_processes[1]	positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
574	6075	6718	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	2	Uncontrolled Retinal Cell Proliferation	Loss of pRB-mediated cell cycle control results in constitutive E2F activity, driving retinal progenitor cells through repeated rounds of DNA replication and cell division. This uncontrolled proliferation leads to tumor formation.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
575	6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			carboplatin	CHEBI:31355	carboplatin		"{""preferred_term"": ""carboplatin"", ""term"": {""id"": ""CHEBI:31355"", ""label"": ""carboplatin""}}"
576	6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			vincristine	CHEBI:27375	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}"
577	6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"
578	6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			melphalan	CHEBI:28876	melphalan		"{""preferred_term"": ""melphalan"", ""term"": {""id"": ""CHEBI:28876"", ""label"": ""melphalan""}}"
579	6089	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	cell_types[0]	muscle cell	CL:0000187	muscle cell	modifier	0	cell_types[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
580	6090	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	cell_types[1]	sensory neuron	CL:0000101	sensory neuron	modifier	0	cell_types[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
581	6091	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	biological_processes[0]	regulation of muscle contraction	GO:0006937	regulation of muscle contraction	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
582	6092	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	biological_processes[1]	skeletal muscle contraction	GO:0003009	skeletal muscle contraction	modifier	0	biological_processes[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
583	6095	6731	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	1	Elevated Upper Esophageal Sphincter Basal Pressure	Patients with R-CPD have significantly higher resting UES pressure compared to healthy controls, contributing to the inability to release trapped gas.	cell_types[0]	muscle cell	CL:0000187	muscle cell	modifier	0	cell_types[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
584	6096	6731	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	1	Elevated Upper Esophageal Sphincter Basal Pressure	Patients with R-CPD have significantly higher resting UES pressure compared to healthy controls, contributing to the inability to release trapped gas.	biological_processes[0]	muscle contraction	GO:0006936	muscle contraction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
585	6175	6830	292	SADDAN	SADDAN.yaml	pathophysiology	1	Constitutive FGFR3 kinase activity	"The Lys650Met mutation causes increased constitutive FGFR3 kinase activity.
"	biological_processes[0]	protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
586	6176	6830	292	SADDAN	SADDAN.yaml	pathophysiology	1	Constitutive FGFR3 kinase activity	"The Lys650Met mutation causes increased constitutive FGFR3 kinase activity.
"	biological_processes[1]	fibroblast growth factor receptor signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
587	6188	6842	292	SADDAN	SADDAN.yaml	treatments	0	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			growth hormone	CHEBI:37845	growth hormone		"{""preferred_term"": ""growth hormone"", ""term"": {""id"": ""CHEBI:37845"", ""label"": ""growth hormone""}}"
588	6201	6852	293	Salla Disease	Salla_Disease.yaml	pathophysiology	1	Loss of Sialin Protein Function	SLC17A5 mutations result in loss or substantial reduction of sialin protein expression or function. Sialin is a 12-transmembrane transporter required for proton-coupled export of free sialic acid (Neu5Ac) from lysosomes to cytosol. Mutations can occur as de novo, inherited biallelic variants, or in mosaic patterns affecting specific tissues.	biological_processes[0]	Sialic acid transport	GO:0015739	sialic acid transport	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
589	6294	6962	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	0	Embryologic developmental disruption	"The anomalies in scimitar syndrome arise from disrupted cardiopulmonary embryogenesis during the fourth to fifth week of gestation. Faulty incorporation of the common pulmonary vein into the left atrium results in the anomalous venous drainage, while abnormal branching morphogenesis of the right lung bud produces ipsilateral pulmonary hypoplasia. Aberrant systemic arterial connections and bronchopulmonary sequestration reflect concurrent errors in vascular patterning. The exact triggers are unknown, and no consistent environmental teratogenic exposure has been identified. The condition is typically sporadic.
"	biological_processes[0]	Lung development	GO:0030324	lung development	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
590	6295	6962	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	0	Embryologic developmental disruption	"The anomalies in scimitar syndrome arise from disrupted cardiopulmonary embryogenesis during the fourth to fifth week of gestation. Faulty incorporation of the common pulmonary vein into the left atrium results in the anomalous venous drainage, while abnormal branching morphogenesis of the right lung bud produces ipsilateral pulmonary hypoplasia. Aberrant systemic arterial connections and bronchopulmonary sequestration reflect concurrent errors in vascular patterning. The exact triggers are unknown, and no consistent environmental teratogenic exposure has been identified. The condition is typically sporadic.
"	biological_processes[1]	Pulmonary vein morphogenesis	GO:0060577	pulmonary vein morphogenesis	modifier	0	biological_processes[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
591	6298	6963	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	1	Anomalous pulmonary venous drainage	"The hallmark of scimitar syndrome is partial or complete anomalous drainage of the right pulmonary veins into the inferior vena cava (IVC) rather than the left atrium. This creates a left-to-right shunt as oxygenated blood from the right lung is returned to the systemic venous circulation instead of the left heart. The anomalous vein typically drains into the IVC at or below the diaphragm, though supradiaphragmatic and hepatic vein drainage variants exist. The hemodynamic significance depends on the proportion of pulmonary venous drainage that is anomalous and the degree of associated right lung hypoplasia.
"	biological_processes[0]	Pulmonary vein morphogenesis	GO:0060577	pulmonary vein morphogenesis	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
592	6301	6964	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	2	Right lung hypoplasia	"The right lung is hypoplastic in most cases, ranging from mild volume reduction to severe underdevelopment with only one or two lobes. Right lung hypoplasia reduces the volume of blood flow through the anomalous circuit, which may paradoxically limit the hemodynamic impact of the left-to-right shunt. The hypoplasia results in dextroposition of the heart (shifting of the mediastinum to the right) rather than true dextrocardia. Right pulmonary artery hypoplasia frequently accompanies lung hypoplasia, further reducing the pulmonary vascular bed.
"	biological_processes[0]	Right lung morphogenesis	GO:0060461	right lung morphogenesis	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
593	6302	6965	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	3	Anomalous systemic arterial supply	"An anomalous systemic artery arising from the thoracic or abdominal aorta supplies part of the right lower lobe in many cases. This arterial supply creates an additional left-to-right shunt by delivering systemic-pressure blood to the pulmonary vascular bed, contributing to pulmonary overcirculation and pulmonary hypertension. Bronchopulmonary sequestration frequently coexists, and aortopulmonary collateral arteries may also be present.
"	biological_processes[0]	Blood vessel development	GO:0001568	blood vessel development	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
594	6358	7030	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	0	AGK loss of function disrupts lipid signaling	"Loss of functional AGK impairs lipid signaling activity attributed to mitochondrial acylglycerol kinase.
"	biological_processes[0]	phosphatidic acid metabolic process	GO:0046473	phosphatidic acid metabolic process	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
595	6360	7032	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	2	Reduced TIM22-mediated import of inner-membrane carrier proteins	"Disruption of the TIM22 complex reduces import of multi-pass carrier proteins and sideroflexins into the inner mitochondrial membrane.
"	biological_processes[0]	protein insertion into mitochondrial inner membrane	GO:0045039	protein insertion into mitochondrial inner membrane	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
596	6361	7033	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	3	Impaired mitochondrial one-carbon metabolism	"Reduced abundance of sideroflexins and one-carbon enzymes disrupts mitochondrial one-carbon metabolism.
"	biological_processes[0]	one-carbon metabolic process	GO:0006730	one-carbon metabolic process	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
597	6362	7034	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	4	Disrupted mitochondrial phospholipid metabolism	"AGK loss alters phospholipid metabolism in mitochondrial membranes, contributing to disease pathogenesis.
"	biological_processes[0]	phospholipid metabolic process	GO:0006644	phospholipid metabolic process	modifier	0	biological_processes[0].modifier	modifier						DYSREGULATED	"""DYSREGULATED"""
598	6363	7035	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	5	Oxidative phosphorylation deficiency	"Impaired respiratory chain function with reduced complex I and V activity and decreased oxygen consumption in patient cells.
"	biological_processes[0]	oxidative phosphorylation	GO:0006119	oxidative phosphorylation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
599	6370	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	treatment_term	coenzyme Q10 supplementation	MAXO:0010012	coenzyme Q10 supplementation	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	coenzyme Q10	NCIT:C916	Coenzyme Q10		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""coenzyme Q10"", ""term"": {""id"": ""NCIT:C916"", ""label"": ""Coenzyme Q10""}}}"
600	6373	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	treatment_term	carnitine supplementation	MAXO:0010006	carnitine supplementation	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	levocarnitine	NCIT:C26657	Levocarnitine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levocarnitine"", ""term"": {""id"": ""NCIT:C26657"", ""label"": ""Levocarnitine""}}}"
601	6376	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term	B vitamin supplementation	MAXO:0000761	B vitamin supplementation	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	thiamine	NCIT:C874	Thiamine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""thiamine"", ""term"": {""id"": ""NCIT:C874"", ""label"": ""Thiamine""}}}"
602	6376	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term	B vitamin supplementation	MAXO:0000761	B vitamin supplementation	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	riboflavin	NCIT:C808	Riboflavin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""riboflavin"", ""term"": {""id"": ""NCIT:C808"", ""label"": ""Riboflavin""}}}"
603	6381	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	treatment_term	ACE inhibitor therapy	MAXO:0000652	ACE inhibitor therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	captopril	NCIT:C340	Captopril		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""captopril"", ""term"": {""id"": ""NCIT:C340"", ""label"": ""Captopril""}}}"
604	6385	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term	diuretic agent therapy	MAXO:0000165	diuretic agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	furosemide	NCIT:C515	Furosemide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""furosemide"", ""term"": {""id"": ""NCIT:C515"", ""label"": ""Furosemide""}}}"
605	6385	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term	diuretic agent therapy	MAXO:0000165	diuretic agent therapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	spironolactone	NCIT:C840	Spironolactone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}"
606	6390	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	levosimendan	NCIT:C174653	Levosimendan		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levosimendan"", ""term"": {""id"": ""NCIT:C174653"", ""label"": ""Levosimendan""}}}"
607	6471	7163	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	0	TP53 Inactivation	TP53 is inactivated in >90% of SCLC through mutations, deletions, or both. Loss of p53 function eliminates the G1/S checkpoint and apoptotic response to DNA damage, enabling survival despite genomic instability.	biological_processes[0]	DNA damage response, signal transduction by p53 class mediator	GO:0030330	DNA damage response, signal transduction by p53 class mediator	modifier	0	biological_processes[0].modifier	modifier						ABSENT	"""ABSENT"""
608	6472	7164	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	1	RB1 Inactivation	RB1 is inactivated in >90% of SCLC through mutations, deletions, or both. Loss of Rb function eliminates the G1/S checkpoint by releasing E2F transcription factors, enabling uncontrolled S-phase entry.	biological_processes[0]	negative regulation of G1/S transition of mitotic cell cycle	GO:0045736	negative regulation of G1/S transition of mitotic cell cycle	modifier	0	biological_processes[0].modifier	modifier						ABSENT	"""ABSENT"""
609	6473	7165	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	2	Loss of Cell Cycle Checkpoints	Combined TP53 and RB1 loss eliminates major cell cycle checkpoints. Cells proliferate rapidly without the normal restraints on replication. This explains the rapid doubling time and initial chemosensitivity (dividing cells are vulnerable to chemotherapy).	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
610	6474	7166	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	3	Genomic Instability	Loss of TP53 and RB1 leads to widespread genomic instability with frequent chromosomal gains and losses. Amplification of MYC family genes (MYC, MYCL, MYCN) occurs in ~20% of SCLC and is associated with worse prognosis.	biological_processes[0]	DNA repair	GO:0006281	DNA repair	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
611	6475	7167	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	4	Neuroendocrine Differentiation	SCLC cells exhibit neuroendocrine differentiation, expressing markers such as synaptophysin, chromogranin A, and CD56 (NCAM). Neuroendocrine phenotype is regulated by lineage transcription factors (ASCL1, NEUROD1). Some SCLC produces paraneoplastic hormones (ACTH, ADH).	biological_processes[0]	neuron differentiation	GO:0030182	neuron differentiation	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
612	6476	7168	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	5	Functional Neuron-SCLC Synapses	SCLC cells can form functional synapses with neurons and receive synaptic transmission.	biological_processes[0]	synapse assembly	GO:0007416	synapse assembly	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
613	6477	7168	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	5	Functional Neuron-SCLC Synapses	SCLC cells can form functional synapses with neurons and receive synaptic transmission.	biological_processes[1]	chemical synaptic transmission	GO:0007268	chemical synaptic transmission	modifier	0	biological_processes[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
614	6478	7169	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	6	Neuron-Driven Proliferation	SCLC cells gain a proliferation advantage when co-cultured with neurons.	biological_processes[0]	positive regulation of cell population proliferation	GO:0008284	positive regulation of cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
615	6479	7170	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	7	Glutamate Signaling Dependency	Inhibition of glutamate signaling has therapeutic efficacy in SCLC models, implicating glutamatergic signaling in tumor growth.	biological_processes[0]	glutamate receptor signaling pathway	GO:0007215	glutamate receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
616	6480	7170	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	7	Glutamate Signaling Dependency	Inhibition of glutamate signaling has therapeutic efficacy in SCLC models, implicating glutamatergic signaling in tumor growth.	biological_processes[1]	synaptic transmission, glutamatergic	GO:0035249	synaptic transmission, glutamatergic	modifier	0	biological_processes[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
617	6596	7307	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	pathophysiology	0	SS18-SSX Fusion Oncogene	The t(X;18)(p11;q11) translocation fuses the SS18 gene on chromosome 18 to one of three SSX genes (SSX1, SSX2, or rarely SSX4) on the X chromosome. The SS18-SSX fusion protein disrupts the BAF (SWI/SNF) chromatin remodeling complex, leading to aberrant transcriptional regulation and epigenetic reprogramming.	biological_processes[0]	chromatin remodeling	GO:0006338	chromatin remodeling	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
618	6597	7308	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	pathophysiology	1	BAF Complex Disruption	The SS18-SSX fusion protein incorporates into the BAF chromatin remodeling complex, displacing wild-type SS18. This alters BAF complex targeting and function, particularly affecting polycomb-mediated gene repression. The fusion protein causes eviction of BAF47 (SMARCB1) from the complex at certain genomic loci.	biological_processes[0]	regulation of gene expression	GO:0010468	regulation of gene expression	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
619	6598	7309	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	pathophysiology	2	Epigenetic Reprogramming	SS18-SSX-containing BAF complexes fail to properly oppose polycomb repressive complexes, leading to abnormal silencing of tumor suppressors and activation of oncogenic programs. Key target genes include BCL2 (antiapoptotic) and multiple receptor tyrosine kinases.	biological_processes[0]	apoptotic process	GO:0006915	apoptotic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
620	6605	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"
621	6605	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
622	6702	7426	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	pathophysiology	1	Hexosaminidase A deficiency	"Lysosomal beta-hexosaminidase A enzyme activity is deficient in Tay-Sachs disease.
"	biological_processes[0]	ganglioside catabolic process	GO:0006689	ganglioside catabolic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
623	6743	7462	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	0	Severe FGFR3 gain-of-function	"TD1 mutations cause severe constitutive activation of FGFR3, leading to profound inhibition of chondrocyte proliferation and differentiation in the growth plate. The R248C mutation in the extracellular domain causes ligand-independent receptor dimerization and activation. This results in severely shortened and disorganized growth plates with minimal longitudinal bone growth.
"	gene	FGFR3	hgnc:3690	FGFR3	modifier	0	gene.modifier	modifier						INCREASED	"""INCREASED"""
624	6760	7475	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	pathophysiology	0	Severe FGFR3 gain-of-function (K650E)	"The K650E mutation in the tyrosine kinase domain causes severe constitutive activation of FGFR3 through autophosphorylation, independent of ligand binding. This profoundly inhibits chondrocyte proliferation and differentiation, resulting in minimal endochondral bone growth. The K650E mutation causes more severe receptor activation than the K650M mutation (associated with SADDAN syndrome).
"	gene	FGFR3	hgnc:3690	FGFR3	modifier	0	gene.modifier	modifier						INCREASED	"""INCREASED"""
625	6802	7514	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	0	Spinal Cord Inflammation	Focal inflammatory injury within the spinal cord disrupts motor and sensory pathways, leading to neurologic deficits.	biological_processes[0]	inflammatory response	GO:0006954	inflammatory response	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
626	6804	7515	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	1	Immune-Mediated Neural Injury	In idiopathic acute transverse myelitis, cellular influx into the spinal cord disrupts the blood-brain barrier and causes demyelination and neuronal injury.	locations[1]	blood brain barrier	UBERON:0000120	blood brain barrier	modifier	0	locations[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
627	6806	7515	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	1	Immune-Mediated Neural Injury	In idiopathic acute transverse myelitis, cellular influx into the spinal cord disrupts the blood-brain barrier and causes demyelination and neuronal injury.	cellular_components[0]	myelin sheath	GO:0043209	myelin sheath	modifier	0	cellular_components[0].modifier	modifier						DECREASED	"""DECREASED"""
628	6824	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	loperamide hydrochloride	NCIT:C62046	Loperamide Hydrochloride		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""loperamide hydrochloride"", ""term"": {""id"": ""NCIT:C62046"", ""label"": ""Loperamide Hydrochloride""}}}"
629	6827	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	ciprofloxacin	NCIT:C376	Ciprofloxacin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""ciprofloxacin"", ""term"": {""id"": ""NCIT:C376"", ""label"": ""Ciprofloxacin""}}}"
630	6830	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	rifaximin	NCIT:C95262	rifaximin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}"
631	6833	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of traveler’s diarrhea.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	bismuth subsalicylate	NCIT:C333	Bismuth Subsalicylate		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bismuth subsalicylate"", ""term"": {""id"": ""NCIT:C333"", ""label"": ""Bismuth Subsalicylate""}}}"
632	6838	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of traveler’s diarrhea in high-risk itineraries with noninvasive E. coli exposure.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	rifaximin	NCIT:C95262	rifaximin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}"
633	6842	7552	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	0	Loss of Hormone Receptor Signaling	TNBC lacks expression of estrogen receptor alpha (ESR1) and progesterone receptor (PGR), eliminating the growth-promoting effects of estrogen signaling that drive most breast cancers. This absence removes a key therapeutic target but also indicates fundamentally different tumor biology.	biological_processes[0]	estrogen receptor signaling pathway	GO:0030520	intracellular estrogen receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						ABSENT	"""ABSENT"""
634	6843	7553	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	1	Alternative Oncogenic Pathways	In the absence of hormone receptor signaling, TNBC is driven by alternative oncogenic pathways including EGFR signaling, PI3K-AKT-mTOR activation, and Wnt/beta-catenin signaling. Many TNBCs have TP53 mutations eliminating this tumor suppressor checkpoint.	biological_processes[0]	epidermal growth factor receptor signaling pathway	GO:0007173	epidermal growth factor receptor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
635	6844	7553	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	1	Alternative Oncogenic Pathways	In the absence of hormone receptor signaling, TNBC is driven by alternative oncogenic pathways including EGFR signaling, PI3K-AKT-mTOR activation, and Wnt/beta-catenin signaling. Many TNBCs have TP53 mutations eliminating this tumor suppressor checkpoint.	biological_processes[1]	phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
636	6845	7554	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	2	DNA Repair Deficiency	A significant subset of TNBC (~20%) harbors germline or somatic BRCA1/2 mutations resulting in homologous recombination deficiency. This creates sensitivity to platinum chemotherapy and PARP inhibitors through synthetic lethality.	biological_processes[0]	homologous recombination	GO:0035825	homologous recombination	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
637	6846	7555	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	3	Aggressive Tumor Behavior	TNBC is characterized by high proliferation rates, early metastasis (especially to viscera and brain), and shorter time to recurrence compared to other breast cancer subtypes. The aggressive biology reflects activation of multiple oncogenic pathways and loss of tumor suppressors.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
638	6945	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	biological_processes[3]	oxidative phosphorylation	GO:0006119	oxidative phosphorylation	modifier	0	biological_processes[3].modifier	modifier						DECREASED	"""DECREASED"""
639	6957	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	biological_processes[1]	autoantibody production			modifier	0	biological_processes[1].modifier	modifier						ABNORMAL	"""ABNORMAL"""
640	7004	7739	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	0	GNAQ/GNA11 Oncogenic Mutations	GNAQ and GNA11 encode alpha subunits of heterotrimeric Gq/11 G-proteins. Mutations at Q209 (most common) or R183 lock the protein in a constitutively active GTP-bound state, resulting in persistent downstream signaling through phospholipase C beta, protein kinase C, and ultimately the MAPK pathway. These mutations are mutually exclusive and early, initiating events.	biological_processes[0]	signal transduction	GO:0007165	signal transduction	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
641	7006	7740	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	1	PKC-MAPK Pathway Activation	Constitutively active GNAQ/GNA11 signaling activates phospholipase C-beta, generating diacylglycerol (DAG) that activates protein kinase C (PKC). PKC in turn activates the RAF-MEK-ERK cascade, driving melanocyte proliferation. This pathway represents a therapeutic target with MEK and PKC inhibitors.	biological_processes[0]	MAPK cascade	GO:0000165	MAPK cascade	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
642	7009	7741	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	2	Uncontrolled Uveal Melanocyte Proliferation	Persistent MAPK signaling drives proliferation of uveal melanocytes, leading to tumor formation. Unlike cutaneous melanoma, uveal melanoma rarely harbors BRAF or NRAS mutations.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
643	7010	7742	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	3	BAP1 Loss and Metastatic Progression	BAP1 (BRCA1-associated protein 1) is a tumor suppressor encoding a deubiquitinase involved in chromatin remodeling and DNA damage response. BAP1 loss occurs in approximately 40% of uveal melanomas and is strongly associated with metastatic disease and poor prognosis. BAP1-deficient tumors exhibit altered gene expression patterns consistent with a more aggressive, less differentiated phenotype.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
644	7053	7811	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	0	VHL Tumor Suppressor Loss	Germline heterozygous VHL mutations result in one functional allele. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates VHL function, initiating tumorigenesis. This follows Knudson's two-hit hypothesis for tumor suppressor gene inactivation.	biological_processes[0]	cellular response to hypoxia	GO:0071456	cellular response to hypoxia	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
645	7054	7812	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	1	Loss of HIF Degradation	VHL protein (pVHL) functions as the substrate recognition component of an E3 ubiquitin ligase complex that targets hydroxylated HIF-alpha subunits for proteasomal degradation under normoxic conditions. Loss of VHL function prevents HIF-alpha degradation, allowing HIF accumulation even in the presence of oxygen.	biological_processes[0]	proteasome-mediated ubiquitin-dependent protein catabolic process	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
646	7055	7813	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	2	Constitutive HIF Activation	Stabilized HIF-alpha (primarily HIF-2alpha in RCC) dimerizes with HIF-1beta (ARNT) and translocates to the nucleus where it activates transcription of hypoxia-responsive genes. This occurs constitutively regardless of oxygen levels, creating a pseudo-hypoxic state.	biological_processes[0]	response to hypoxia	GO:0001666	response to hypoxia	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
647	7056	7814	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	3	VEGF Overexpression and Angiogenesis	VEGF (vascular endothelial growth factor) is a direct HIF target gene. Constitutive HIF activation leads to chronic VEGF overexpression, driving extensive tumor angiogenesis. This explains the highly vascular nature of VHL-associated tumors, particularly hemangioblastomas and clear cell RCC.	biological_processes[0]	vascular endothelial growth factor signaling pathway	GO:0038084	vascular endothelial growth factor signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
648	7057	7814	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	3	VEGF Overexpression and Angiogenesis	VEGF (vascular endothelial growth factor) is a direct HIF target gene. Constitutive HIF activation leads to chronic VEGF overexpression, driving extensive tumor angiogenesis. This explains the highly vascular nature of VHL-associated tumors, particularly hemangioblastomas and clear cell RCC.	biological_processes[1]	angiogenesis	GO:0001525	angiogenesis	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
649	7058	7815	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	4	Growth Factor and Metabolic Reprogramming	HIF activates transcription of genes including PDGF, TGF-alpha, EGFR, GLUT1, and glycolytic enzymes. This promotes cell proliferation, survival, and a shift toward glycolytic metabolism (Warburg effect) that supports tumor growth.	biological_processes[0]	cellular glucose homeostasis	GO:0001678	cellular glucose homeostasis	modifier	0	biological_processes[0].modifier	modifier						ABNORMAL	"""ABNORMAL"""
650	7059	7815	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	4	Growth Factor and Metabolic Reprogramming	HIF activates transcription of genes including PDGF, TGF-alpha, EGFR, GLUT1, and glycolytic enzymes. This promotes cell proliferation, survival, and a shift toward glycolytic metabolism (Warburg effect) that supports tumor growth.	biological_processes[1]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[1].modifier	modifier						INCREASED	"""INCREASED"""
651	7096	7859	341	Wilms Tumor	Wilms_Tumor.yaml	pathophysiology	0	WT1 Inactivation	WT1 is a transcription factor essential for normal kidney and gonad development. Biallelic WT1 inactivation occurs in 10-20% of Wilms tumors. Germline WT1 mutations cause WAGR syndrome (Wilms tumor, aniridia, genitourinary anomalies, intellectual disability) and Denys-Drash syndrome.	biological_processes[0]	cell differentiation	GO:0030154	cell differentiation	modifier	0	biological_processes[0].modifier	modifier						DECREASED	"""DECREASED"""
652	7098	7860	341	Wilms Tumor	Wilms_Tumor.yaml	pathophysiology	1	WTX/CTNNB1 Wnt Pathway Activation	WTX (AMER1) is a negative regulator of Wnt signaling mutated in approximately 15-20% of Wilms tumors. CTNNB1 (beta-catenin) activating mutations occur in approximately 15% of cases. Both result in constitutive Wnt pathway activation, promoting proliferation and blocking differentiation.	biological_processes[0]	Wnt signaling pathway	GO:0016055	Wnt signaling pathway	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
653	7099	7861	341	Wilms Tumor	Wilms_Tumor.yaml	pathophysiology	2	Blocked Nephron Differentiation	Wilms tumor arises from nephrogenic rests - foci of embryonic blastemal cells that persist beyond the normal period of nephrogenesis. These cells retain proliferative capacity but fail to undergo terminal differentiation into mature nephrons.	biological_processes[0]	cell population proliferation	GO:0008283	cell population proliferation	modifier	0	biological_processes[0].modifier	modifier						INCREASED	"""INCREASED"""
654	7107	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"
655	7107	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
656	7107	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
657	7147	7902	342	Wilson Disease	Wilsons_Disease.yaml	treatments	2	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			zinc acetate	CHEBI:62984	zinc acetate		"{""preferred_term"": ""zinc acetate"", ""term"": {""id"": ""CHEBI:62984"", ""label"": ""zinc acetate""}}"
658	7150	7904	342	Wilson Disease	Wilsons_Disease.yaml	treatments	4	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.	treatment_term	copper chelator agent therapy	MAXO:0001224	copper chelator agent therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			tetrathiomolybdate	CHEBI:30703	tetrathiomolybdate(2-)		"{""preferred_term"": ""tetrathiomolybdate"", ""term"": {""id"": ""CHEBI:30703"", ""label"": ""tetrathiomolybdate(2-)""}}"
659	7167	7924	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	0	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.	treatment_term	NSAID therapy	MAXO:0000221	NSAID therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			naproxen	NCIT:C680	Naproxen		"{""preferred_term"": ""naproxen"", ""term"": {""id"": ""NCIT:C680"", ""label"": ""Naproxen""}}"
660	7170	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	dapsone	NCIT:C415	Dapsone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dapsone"", ""term"": {""id"": ""NCIT:C415"", ""label"": ""Dapsone""}}}"
661	7173	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	azathioprine	NCIT:C290	Azathioprine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}"
